Risk Factors for Postoperative Cognitive Dysfunction in Older Adults Undergoing Major Noncardiac Surgery by Shoair, Osama
Virginia Commonwealth University 
VCU Scholars Compass 
Theses and Dissertations Graduate School 
2013 
Risk Factors for Postoperative Cognitive Dysfunction in Older 
Adults Undergoing Major Noncardiac Surgery 
Osama Shoair 
Virginia Commonwealth University 
Follow this and additional works at: https://scholarscompass.vcu.edu/etd 
 Part of the Pharmacy and Pharmaceutical Sciences Commons 
 
© The Author 
Downloaded from 
https://scholarscompass.vcu.edu/etd/503 
This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It 
has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars 
Compass. For more information, please contact libcompass@vcu.edu. 
 
 
 
 
 
 
 
 
 
© Osama A. Shoair, 2013 
All Rights Reserved 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RISK FACTORS FOR POSTOPERATIVE COGNITIVE DYSFUNCTION IN OLDER 
ADULTS UNDERGOING MAJOR NONCARDIAC SURGERY 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy at Virginia Commonwealth University 
 
 
 
By 
OSAMA A. SHOAIR 
Bachelors in Pharmaceutical Sciences, Misr International University, Cairo, Egypt, 2005 
Certificate in Aging Studies, Virginia Commonwealth University, Richmond, Virginia, 2013 
 
 
 
 
Director: PATRICIA W. SLATTUM, PHARM.D., PH.D. 
Associate Professor and Director of Geriatric Pharmacotherapy Program 
Department of Pharmacotherapy and Outcomes Science 
 
 
 
 
Virginia Commonwealth University 
Richmond, Virginia 
May 2013 
i 
 
 
 
 
 
Acknowledgement 
 
 
I would like to thank God for his help and support through this long journey until I 
finished this piece of work. I thank him for everything he has gifted me with and I pray for him 
to continue his support to me through my life. He has provided me with very supportive people, 
without whom, I could not have done this piece of work. 
My gratitude goes to my graduate advisor and mentor, Dr. Patricia Slattum who 
individualized my experience through the graduate program and helped me achieve my career 
aspirations. She provided me with several opportunities for personal and professional 
development and allowed me the time to do the things that would prepare me to be very 
successful in the academia after graduation. She was very understanding of my capabilities and 
skills and she worked hard with me on fine tuning these skills. She also supported me in times of 
distress and disappointments, and was always willing to go the extra mile to make things easier 
for me in career and life. I was lucky to be mentored by Dr. Patricia Slattum who is such a great 
person on professional and personal levels. 
I would like to thank Dr. Chuck Biddle and Dr. Mario Grasso whom I was so lucky to 
cross path with during our collaboration in this research study. Our relationship has developed 
over years to become one of the best relationships I ever had in my career. For me, they were 
mentors, friends, and sometimes big brothers. I will never forget all the time and effort Dr. 
Grasso has put in this piece of work, not only because he wanted this study to come to light, but 
also because he cared about my personal development and success. Dr. Biddle has been a second 
ii 
 
 
 
mentor to me who provided guidance, inspiration, and support, and he was my person-to-go 
when I was frustrated with any obstacles I experienced during the study or in my life in general. 
Drs. Biddle and Grasso provided me with their invaluable clinical experience and were able to 
help me completely understand how things exactly work in a completely different area of 
expertise. They were also very successful communicators when it came to getting surgeons, 
anesthesia care providers, nurses, and staff to support this research study. I have to admit that 
this study could not have happened without the full support of Drs. Biddle and Grasso. 
I would like to thank all the members of my advisory committee for their time and advice 
throughout the graduate program. The discussions we had at each step of the process of 
conducting my research project, and the critiques I received from them were very constructive 
and important to the success of this study. 
I thank my parents for helping me throughout my whole life and they are part of all my 
successes. They did me the greatest favor when they invested in my education, and they were not 
selfish when I had to stay away from them for all these years to pursue my graduate education. 
They always had trust and confidence in me starting when I was so young and this made me the 
responsible person I am, and it encouraged me to stay passionate and genuine about whatever I 
do. 
I would like to thank my colleagues Yaena Min and May Abdel Aziz for helping me with 
data collection for this study. They were very supportive and willing to spare the time to help me 
as much as they could. Without May and Yaena, I could have lost a lot of patients and I owe 
them part of this success. 
iii 
 
 
 
The best support system I had in my life were my friends back home in Egypt. Even after 
relocating to the U.S., they continued to support and motivate me to achieve my goals over all 
these years. They are a major part of my success and I would like to thank them all very much 
for over a decade of a very successful, respectable, and supportive friendship. 
Most importantly, my gratitude and love goes to my wife; May Abdel Aziz, and my three 
year-old daughter; Salma. My wife had confidence in my ability to succeed the first time we met 
five years ago. Together, we worked hard to join graduate school and we were so lucky to join 
Virginia Commonwealth University together. Through these last five years, she did everything in 
her ability to help me achieve my goals and I will always remember that for her. I also do 
appreciate the understanding and patience of my daughter in times I have been short in giving 
her the time and care such a wonderful princess deserves. I promise to make it up for her soon 
after graduation. 
Last but not least, I would like to acknowledge the funding support we received from the 
‘VCU Presidential Research Quest Fund’ that supported our study. I do thank the university 
president for his commitment to develop and enhance scholarship across the institution as part of 
‘VCU Quest for Distinction’ with focus on real collaborative interdisciplinary research like our 
project. 
 
 
 
iv 
 
 
 
 
Table of Contents 
LIST OF TABLES ....................................................................................................................  viii 
LIST OF FIGURES ....................................................................................................................  ix 
LIST OF ABBREVIATIONS .....................................................................................................  x 
ABSTRACT ................................................................................................................................  xii 
CHAPTER 1: INTRODUCTION 
I. Definition of POCD  ...............................................................................................................1 
II. Incidence of POCD  ..............................................................................................................3 
III. Postoperative Delirium (POD) and POCD  .........................................................................4 
IV. Long-term consequences of POCD  ....................................................................................5 
V. Risk Factors for POCD  ........................................................................................................5 
VI. Summary  .............................................................................................................................6 
VII. References  .........................................................................................................................8 
CHAPTER 2: LITERATURE REVIEW 
I. Etiology and Risk Factors of POCD  ...................................................................................11 
A. Medications  ...........................................................................................................12 
v 
 
 
 
1. Anesthesia/Sedation  .................................................................................12 
2. Home and Perioperative Medications  ......................................................16 
3. Postoperative Medications  .......................................................................18 
B. Surgery  ..................................................................................................................20 
1. Type of Surgery  .......................................................................................20 
2. Intraoperative Conditions  ........................................................................21 
3. Neuroinflammation and Brain Injury Biomarkers  ...................................24 
4. Postoperative Delirium  ............................................................................26 
5. Postoperative Complications  ...................................................................26 
C. Patient  ...................................................................................................................27 
1. Age  ...........................................................................................................27 
2. Cognitive Reserve  ....................................................................................27 
3. Pre-existing Cognitive Impairment Before Surgery  ................................28 
4. Genetic Biomarkers  .................................................................................29 
5. Comorbidities  ..........................................................................................30 
II. Summary  ............................................................................................................................31 
III. Discussion  .........................................................................................................................32 
vi 
 
 
 
IV. References  ........................................................................................................................33 
CHAPTER 3: SIGNIFICANCE AND SPECIFIC AIMS 
I. Significance  .........................................................................................................................40 
II. Specific Aims  .....................................................................................................................42 
III. Summary  ...........................................................................................................................42 
CHAPTER 4: METHODS 
I. Study Population  .................................................................................................................43 
II. Type of Surgery and Anesthesia .........................................................................................44 
III. Outcome Assessment  ........................................................................................................44 
IV. Assessment of Postoperative Delirium (POD)  .................................................................48 
V. Depression and Sleep Quality Testing  ...............................................................................48 
VI. Data Collection  .................................................................................................................50 
VII. ApoE Genotyping  ............................................................................................................50 
VIII. Inflammatory Biomarker Analysis  ................................................................................52 
IX. Statistical Analysis  ...........................................................................................................52 
A. Specific Aim #1  ....................................................................................................53 
B. Specific Aim #2  ....................................................................................................54 
vii 
 
 
 
X. References  ..........................................................................................................................57 
CHAPTER 5: RESULTS 
I. Demographics and Baseline Characteristics of Study Subjects ...........................................59 
II. Depression Status and Sleep Quality at Baseline and Follow-up .......................................63 
III. Incidence and Risk Factors of POCD  ...............................................................................69 
IV. Summary  ...........................................................................................................................76 
CHAPTER 6: DISCUSSION 
I. Incidence of POCD  ..............................................................................................................77 
II. Risk Factors for POCD .......................................................................................................80 
III. Study Limitations  ..............................................................................................................84 
IV. Future Directions  ..............................................................................................................87 
V. Conclusion  .........................................................................................................................89 
VI. References  ........................................................................................................................90 
APPENDICES 
Appendix A: Approved Consent form for Study Surgical Group ...........................................94 
Appendix B: Approved Consent form for Study Nonsurgical Group  ..................................101 
VITA............................................................................................................................................106 
viii 
 
 
 
 
List of Tables 
 
CHAPTER 1: INTRODUCTION 
Table 1: Summary of Major Differences between POCD and POD  ........................................5 
CHAPTER 5: RESULTS 
Table 1: Demographics and Baseline Characteristics of Surgical and Nonsurgical Groups  ..62 
Table 2: Comparison of Depression Status within Surgical and Nonsurgical Groups at 
Baseline and Three-Month Follow-up as Measured by GDS-SF  .............................64 
Table 3: Comparison of Sleep Quality within Surgical and Nonsurgical Groups at Baseline 
and Three-Month Follow-up as Measured by PSQI  .................................................65 
Table 4: Comparison of Depression Status between Surgical and Nonsurgical Groups at 
Baseline and Follow-up as Measured by GDS-SF  ...................................................67 
Table 5: Comparison of Sleep Quality between Surgical and Nonsurgical Groups at Baseline 
and Follow-up as Measured by PSQI  .......................................................................68 
Table 6: Results of the Univariable Analysis for Initial Screening of Potential Risk Factors 
for POCD ...................................................................................................................70 
Table 7: Results of Multivariable Logistic Regression showing Risk Factors for POCD  ......75 
 
ix 
 
 
 
 
List of Figures 
 
CHAPTER 2: INTRODUCTION 
Figure 1: Major Theories and Risk Factors of POCD  ............................................................12 
CHAPTER 4: METHODS 
Figure 1: Summary of Data Collection Process from Baseline to Follow-up  ........................51 
CHAPTER 5: RESULTS 
Figure 1: Recruitment Process for the Study Surgical Group  .................................................60 
Figure 2: Recruitment Process for the Study Nonsurgical Group  ..........................................61 
 
 
 
 
 
 
 
 
x 
 
 
 
 
List of Abbreviations 
 
  
AD Alzheimer’s disease 
ANOVA Analysis of variance 
ApoE4 Apolipoprotein-E4 
BDZs Benzodiazepines 
BIS Bispectral index 
CA Coronary angiography 
CABG Coronary artery bypass grafting 
CAM Confusion Assessment Method 
CBP Cardiopulmonary bypass 
CI Confidence interval 
CLSI Clinical and Laboratory Standards Institute 
CRP C-reactive protein 
CSI Cerebral state index 
CV Coefficient of variation 
DSM-IV-TR Diagnostic and Statistical Manual for Mental Disorders (Fourth 
Edition, Text Revision) 
GA General anesthesia 
GDS-SF Geriatric Depression Scale, Short-Form 
ICD International classification of diseases 
IL Interleukin 
IRB Institutional Review Board 
ISPOCD International Study of Postoperative Cognitive Dysfunction 
MCI Mild cognitive impairment 
MMSE Mini-Mental State Examination 
NSE Neuron-specific enolase 
OR Odds ratio 
xi 
 
 
 
PACU Post-anesthesia care unit 
PCA Patient-controlled analgesia 
PCI Preoperative cognitive impairment 
PEG Polyethylene glycol 
POCD Postoperative cognitive dysfunction 
POD Postoperative delirium 
PSQI Pittsburgh Sleep Quality Index 
RA Regional anesthesia 
REDCap™ Research Electronic Data Capture 
SD Standard deviation 
THJR Total hip joint replacement 
TKA Total knee arthroplasty 
TNF- α Tumor-necrosis factor-alpha 
VCUHS Virginia Commonwealth University Health System 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xii 
 
 
 
 
 
 
Abstract 
 
 
 
 
RISK FACTORS FOR POSTOPERATIVE COGNITIVE DYSFUNCTION IN OLDER 
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Virginia Commonwealth University, 2013 
 
 
Major Director: Patricia W. Slattum, Pharm.D., Ph.D. 
Associate Professor and Director of Geriatric Pharmacotherapy Program 
Department of Pharmacotherapy and Outcomes Science 
 
 
 
Background: Postoperative cognitive dysfunction (POCD) is a deterioration in cognitive 
function that occurs after surgery as measured by neuropsychological tests. The purpose of this 
study was to determine the incidence and risk factors for POCD in older adults three months 
after major noncardiac surgery. 
Methods: This is a prospective study of patients aged 65 years and older who underwent major 
noncardiac surgery. Patients’ cognitive function was assessed before and three months after 
surgery using a computerized neurocognitive battery. Blood samples were withdrawn from 
patients before surgery to identify patients with high level of C-reactive protein (CRP), and 
patients who had the apolipoprotein-E4 (ApoE4) allele, as potential inflammatory and genetic 
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biomarkers for POCD, respectively. A nonsurgical control group, that is similar to patients in 
age, education level, and computer familiarity, was recruited to adjust for learning effects from 
repeated administration of neurocognitive tests. Patients were classified as having POCD if they 
had less than -1.96 in the individual Z-scores of two or more tests or in the composite Z-score. 
Results: A total of 69 patients and 54 controls completed the study. The mean age for patients 
was 71 ± 5.4 (65–88) years old and 66.7% of them were females. The majority of patients 
(78.3%) had above high school education. There was no difference between the surgical and 
nonsurgical groups in demographics except for age which was marginally higher in the 
nonsurgical group [73 ± 6.3 (65-92)]. 
The incidence of POCD was 15.9% three months after surgery. Multivariable logistic regression 
showed that carrying the ApoE4 allele (OR = 4.74, 95% CI = 1.09 – 22.19), using one or more 
highly anticholinergic or sedative-hypnotic drugs at home prior to surgery (OR = 5.64, 95% CI = 
1.35 – 30.22), and receiving sevoflurane for anesthesia (OR = 6.43, 95% CI = 1.49 – 34.66) were 
risk factors for POCD. 
Conclusion: The incidence of POCD in older adults is 15.9% three months after major 
noncardiac surgery. Risk factors for POCD were carrying the ApoE4 allele, using one or more 
highly anticholinergic or sedative-hypnotic drugs at home prior to surgery, and receiving 
sevoflurane for anesthesia. 
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CHAPTER 1: INTRODUCTION 
 
Postoperative cognitive dysfunction (POCD) is a deterioration in cognitive function that 
occurs to patients after surgery as compared to their preoperative cognitive status. POCD is not a 
new phenomenon and it has been well-documented in the literature for a very long time. About 
fifty five years ago, Bedford published a retrospective observational report of 251 older patients 
over the age of 65 years who experienced deterioration in their cognitive function after surgery 
as was described by the patients or their family members.1,2 He observed, without performing 
any neuropsychological testing, that a minor degree of dementia was present in this group and 
that 7% of them experienced severe dementia to the extent that he suggested that “operations on 
elderly people should be confined to unequivocally necessary cases”.1 Most of the research 
initially focused on POCD in cardiac surgery since the proportion of patients who experienced 
decline in cognitive function after this type of surgery was large compared to other types of 
surgery. POCD is now recognized as a potential complication of cardiac surgery and current 
research is trying to elucidate the risk factors of POCD in this type of surgery, particularly the 
role of cardiopulmonary bypass (CPB) in contributing to POCD.3 In contrast, the research about 
the incidence and risk factors of POCD after noncardiac surgery is still in its infancy, and the 
results of current research in this area is still conflicting and inconclusive. 
 
I. DEFINITION OF POCD 
Currently, there is no consensus definition of POCD in the literature. For research 
purposes, POCD is generally defined as a decline or deterioration in cognitive function that 
occurs in patients after surgery when compared to their preoperative cognitive status as measured 
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by neuropsychological testing. This decline is usually subtle in nature and is observed most of 
the time by the patients, their caregivers, or close friends. A statement from a patient such as “I 
am not the same” after surgery can simply represent the patient’s lay language of having POCD 
in the absence of a gold standard tool to diagnose it. POCD can affect different cognitive 
domains including verbal memory, visual memory, processing speed, cognitive flexibility, and 
executive function.4 Due to its often subtle nature, the condition can usually be missed by 
clinicians, and an appropriate battery of neurocognitive tests, that is sensitive to subtle changes in 
cognitive function and covers a wide array of cognitive abilities, is necessary to determine if a 
patient is having POCD. 
 The risk of POCD may be increased in older adults due to various changes associated 
with physiology of aging. Cerebral changes occur to the brain as we age including reduction of 
the complexity of neuronal connections, reduction of the synthesis of neurotransmitters, and 
increase in the postsynaptic degradation of neurotransmitters.5 The changes may also include 
decreased regional brain volume, impaired serotonin, acetylcholine, and dopamine receptor 
binding and signaling, accumulation of neurofibrillary tangles, and altered concentrations of 
various brain metabolites.6-11 There are also pharmacokinetic and pharmacodynamic changes that 
progressively occur with aging.12 Pharmacokinetic changes include a reduction in renal and 
hepatic clearance and increase in volume of distribution of lipid soluble drugs resulting in 
prolongation of elimination half-life of several drugs.12 Pharmacodynamic changes involve 
altered, usually increased, sensitivity to several classes of drugs including medications with 
anticholinergic and sedative properties that are known to cause negative cognitive outcomes.12 
These changes may also cause the brain of older patients to have less tolerability to anesthetic 
drugs and other highly anticholinergic and sedative-hypnotic medications during the surgery 
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which may increase vulnerability of older adult patients to neurologic deterioration and various 
insults that happen to the brain during surgery.  
 
II. INCIDENCE OF POCD 
The reported incidence of POCD in the literature after both cardiac and noncardiac 
surgery is enormously variable and should be interpreted cautiously. This is due to several 
factors including the wide variability in the definition of POCD, number of cognitive domains 
assessed, number and type of neurocognitive tests used to assess each cognitive domain, time of 
pre- and postoperative assessment of cognitive function, type of surgery and anesthesia, and the 
use of a control group to adjust for learning effects from repeated administration of 
neurocognitive tests. The incidence of POCD has been reported to be 30 – 80% a few weeks 
after cardiac surgery, and 10 – 60% after three to six months.2 The first International Study of 
Postoperative Cognitive Dysfunction (ISPOCD1) reported the incidence of POCD after major 
noncardiac surgery to be 25.8% one week after surgery and 9.9% after 3 months.13 Newman et 
al. conducted a meta-analysis showing that the incidence of POCD after noncardiac surgery in 
studies published until December 2005, ranged between 6.2% and 56% 22 days and up to six 
months aftersurgery.1 Ignoring the one study with very high incidence of POCD, the incidence 
range was between 6.2% and 9.4%.1 These reports reveal how difficult it is to obtain accurate 
estimates of the incidence of POCD after different types of surgery. As mentioned earlier, this is 
due to the wide variability in the methodology used to determine the incidence of POCD. This 
also makes it very difficult to compare the results of different POCD studies. 
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III. POSTOPERATIVE DELIRIUM (POD) AND POCD 
POCD may be confused with postoperative delirium (POD), and may mistakenly be 
considered as part of the same continuum. However, despite their similarities, POCD and POD 
are two distinct phenomena. POD is well defined in the World Health Organization’s 
classification of diseases (ICD-10) and the Diagnostic and Statistical Manual for Mental 
Disorders [fourth edition, text revision] (DSM-IV-TR).14 POD is characterized by an acute onset 
of altered consciousness, disorientation, and confusion which starts hours to days after surgery 
and can last for days to weeks. In most patients, POD often occurs within the first three days 
after surgery.14 Attention is usually impaired in POD and may be associated with fluctuation in 
consciousness.14 POD is usually reversible especially if the clinician can determine its 
underlying cause.14 POD can be assessed using several valid and reliable tools such as the 
Confusion Assessment Method (CAM).15 
On the other hand, POCD does not have a consensus definition or ICD diagnostic codes 
and its onset is subtle in nature. POCD is generally not well-characterized and the major 
complaint of patients with POCD would be a general deterioration in memory or other cognitive 
domains that may make it hard enough for some patients to manage their job or daily activities.14 
The onset of POCD usually occurs within weeks to months after surgery and may last for years 
or become permanent. The number and type of affected cognitive domains in POCD widely 
vary, but consciousness is not altered in POCD.14 POCD may be reversible but it can also be 
long lasting in some patients.14 There is no current consensus on the number or type of 
neurocognitive tests that should be used to diagnose POCD. Table 1 summarizes the major 
differences between POCD and POD. 
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IV. LONG-TERM CONSEQUENCES OF POCD 
POCD is a serious phenomenon and should not be underestimated by patients, caregivers, 
or clinicians. Monk et al. showed an association between POCD and increased mortality in 
patients in the first year after major noncardiac surgery.17 Patients with POCD at hospital 
discharge were more likely to die before the three-month follow-up cognitive testing, and 
patients who continued to have persistent POCD after three months were at higher risk of death 
in the first year after surgery.18 Another study showed that POCD after noncardiac surgery was 
associated with increased mortality, decreased quality of life, risk of early withdrawal from the 
workforce, and increased dependency on society.19,20 
 
Table 1. Summary of Major Differences between POCD and POD (Adapted from Krenk et al.)14 
Features POD POCD 
Definition and Severity ICD-9/10, DSM-IV-TR Controversial 
Incidence 4 – 54%16 7 – 71%1 
Onset Acute (hours to days) Subtle (weeks to months) 
Duration Days to weeks Weeks to years 
Cognitive Changes Attention Multiple/Variable 
Consciousness Altered Normal 
Reversibility Usually reversible May be reversible 
 
 
V. RISK FACTORS FOR POCD 
The mechanisms and risk factors for POCD are still unknown, and POCD is likely a 
multifactorial condition. The next chapter will discuss three major theories in the current 
literature that may play a role in the development of POCD. The first theory is related to surgery 
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and it includes several factors such as type of surgery, possible neuroinflammation during 
surgery, postoperative delirium, and postoperative complications. The second theory is 
concerned about medications being administered to the patients including home medications 
prior to surgery, anesthesia and sedation during surgery, and postoperative analgesics. The third 
theory puts the ‘fault’ on the patient and suggests that POCD may be associated with patient’s 
age, education level, predisposition with certain genes related to cognitive deterioration, and 
other factors. The next chapter will elaborate in detail on each of these variables and the 
literature supporting it. 
 
VI. SUMMARY 
POCD does not have a consensus definition in the literature, but it can be generally 
defined as a deterioration in patients’ cognitive function after surgery compared to their 
preoperative cognitive status as measured by neuropsychological testing. POCD has primarily 
been documented after cardiac surgery, but it has been recently reported after noncardiac surgery 
as well. POCD is usually subtle in nature and may be underestimated by clinicians. The 
incidence of POCD in the literature widely varies depending on the definition of POCD, number 
of cognitive domains assessed, number and type of neurocognitive tests used to assess each 
cognitive domains, time of pre- and postoperative assessment of cognitive function, type of 
surgery and anesthesia, and the use of a control group to adjust for learning effects. POCD is 
usually confused with POD after surgery though they are different in the onset, duration, 
cognitive changes, alteration of consciousness, and possible reversibility. POCD has long-term 
consequences that may range from decreased quality of life to mortality. The risk factors for 
POCD are still unknown and POCD is likely to be multifactorial. Potential risk factors for POCD 
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may be related to surgery, medications, or the patient. The next chapter will discuss these risk 
factors in detail and the literature supporting them. 
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CHAPTER 2: LITERATURE REVIEW 
 
I. ETIOLOGY AND RISK FACTORS OF POCD 
The etiology and pathophysiologic mechanisms of POCD remain unknown and POCD is 
likely a multifactorial condition. Currently, there are three major theories that may explain 
POCD: medication, surgery, and patient theories.1,2 Each of these theories includes several 
potential risk factors for POCD. First, there is the medication theory which suggests that certain 
anesthetic and sedatives agents administered during and after the surgery may be etiological in 
POCD, particularly those medications with highly anticholinergic or sedative properties. This 
theory also extends to medications that the patient has been chronically using at home prior to his 
admission to surgery. Second is the surgery theory that is inclusive of factors related to the type 
and duration of the surgery, intraoperative conditions and physiologic changes that occur during 
the surgery, possible inflammation or traumatic injury to the brain, postoperative delirium, length 
of hospitalization, and postoperative complications such as infection or respiratory depression. A 
third theory suggests that it might not be the medication or the surgery theories, and that it is 
basically the patient’s ‘fault’.1 This theory suggests that patients’ age, cognitive reserve or the 
ability to sustain neurologic insults, pre-existing cognitive impairment before surgery, genetic 
predisposition related to dementia such as the apolipoprotein-E4 (ApoE4) allele, chronic 
depression or anxiety prior to surgery, alcoholism or chronic smoking, and their comorbidities 
may be associated with the risk of POCD. Figure 1 shows a summary of the three current major 
theories and risk factors of POCD. The most important candidate risk factors that might play 
independent or collaborative roles in the genesis of POCD will be discussed in detail. 
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Figure 1. Major Theories and Risk Factors of POCD 
 
A. MEDICATIONS 
1. Anesthesia/Sedation 
 The role of general anesthesia (GA) in causing cognitive dysfunction has often been 
described as a potential risk factor for POCD especially in older adults.3 Animal studies showed 
that long exposure to common anesthetic agents can cause cell damage and apoptosis.4 Jevtovic-
Todorovic et al. found cell death in rat brains after exposure to midazolam, nitrous oxide, and 
isoflurane, and when combining all three agents, there was a significant decline in their memory 
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and learning skills.4 However, these observations might not be transferable to humans and there 
is a need to accumulate evidence in humans to determine if they are related to the type, duration, 
or depth of anesthesia. Few studies have been conducted to evaluate if there is an association 
between POCD and the type of anesthesia [general (inhaled, intravenous), regional (spinal, 
epidural, or nerve block), or both general and regional anesthesia], duration of anesthesia, and 
depth of anesthesia. Also, there is an increased interest in studying the risk of POCD associated 
with the use of sedative agents during surgery. 
Rasmussen et al. randomized 428 patients aged 60 years and older undergoing major 
noncardiac surgery for GA versus regional anesthesia (RA).5 They evaluated patients’ cognitive 
function seven days and three months after surgery finding a significant difference in POCD 
incidence at seven days between the GA and RA groups [21.2% versus 12.7% (p = 0.04)], 
respectively.5 However, at the three-month follow-up, there was no significant difference in the 
incidence of POCD between the two groups (14.3% after GA and 13.9% after RA).5 Evered et al. 
also compared the incidence of POCD three months postoperatively after GA and RA, but they 
could not find a significant difference (21% vs. 16%, respectively).6 They concluded that POCD 
is independent of the type of anesthesia used during the surgery.6 Mason et al. conducted a meta-
analysis to compare the influence of general, regional, or a combination of GA and RA on the 
development of POCD.7 They compared the incidence of POCD when patients were 
administered GA versus individual types of RA and also the combination of GA and RA, but 
they could not find a significantly higher incidence of POCD with any of these comparisons.7 
This meta-analysis was limited by the major weakness of all POCD studies which is the 
difficulty of combining and comparing different studies due to the wide variability in 
methodological techniques of POCD assessment. 
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There is a scarcity of research to evaluate the relationship between the duration of 
anesthesia and POCD. Moller et al. evaluated the duration of anesthesia as a risk factor for 
POCD in a group of 1218 older patients 60 years and above undergoing major noncardiac 
surgery at seven days and three months.8 They compared the difference in POCD incidence 
when patients were under anesthesia for a duration of 120 minutes or less, 121 – 240 minutes, 
and 241 minutes or longer.8 They found that the duration of anesthesia was associated with 
POCD incidence at seven days (18%, 24%, and 33%, respectively) but not three months after 
surgery (11%, 9%, and 11%, respectively).8 
A few studies have evaluated the depth of anesthesia as a risk factor for POCD. 
Steinmetz et al. studied 70 patients aged 60 years or older who underwent major noncardiac 
surgery.3 The depth of anesthesia was monitored using the cerebral state monitor, which 
provided a cerebral state index (CSI) value.3 The duration of anesthesia was not different in 
patients with deep anesthesia (CSI < 40) and light anesthesia (CSI > 60).3 They were not able to 
find a significant difference in the incidence of POCD between the two groups at seven days 
after surgery and they did not do any further follow-up.3 However, this study was underpowered 
and there was the possibility of type II error.3 Farag et al. randomized 74 patients older than 50 
years to either a lower Bispectral Index (BIS) anesthesia regimen (median = 39) or a higher BIS 
regimen (median = 51) during the surgical procedure.9 Patients’ cognitive status was assessed 
preoperatively and four to six weeks after surgery using a cognitive battery that included tests to 
measure processing speed, working memory, and verbal memory.9 Processing speed was the 
only significantly different test between the two groups with higher processing speed observed in 
the group with lower BIS or deeper depth of anesthesia. There was no significant difference 
between the two groups with the other two cognitive tests.9 Chan et al. randomized patients 60 
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years or older undergoing any elective major surgery to receive BIS-guided anesthesia or routine 
care.10 There was a significant difference between the two groups in depth of anesthesia (BIS 
median = 53 and 36; p < 0.001, respectively).10 There was no significant difference between the 
two groups in cognitive function seven days after surgery.10 However, three months after the 
surgery, the patients in the BIS-guided group with lighter depth of anesthesia had a lower 
incidence of POCD compared with the routine care group with deeper level of anesthesia (10.2% 
vs. 14.7%; adjusted odds ratio (OR) = 0.67; 95% confidence interval (CI) = 0.32 – 0.98; p = 
0.025).10 This study suggests that lighter depth of anesthesia is associated with better long-term 
cognitive outcomes after major surgery. 
Royse et al. investigated the influence of propofol or desflurane on the incidence of 
POCD in a randomized trial of 180 patients undergoing coronary artery bypass surgery 
(CABG).11 They found that the incidence of POCD was significantly higher with propofol 
compared with desflurane when they assessed patients’ cognitive function three to seven days 
after surgery (67.5% vs. 49.4%, respectively; p = 0.018).11 However, there was no difference in 
the incidence of POCD with propofol compared with desflurane at three months after surgery 
(11.2% vs. 10.0%, respectively).11 The results of this study show that propofol may increase the 
risk of short-term POCD after cardiac surgery. Höcker et al. randomized patients 65 years and 
older undergoing elective abdominal or urologic surgery to receive anesthesia with sufentanil 
and either propofol or xenon.12 Patients’ cognitive function was assessed one, six, and thirty days 
after surgery.12 The study also showed a high incidence of POCD with the use of propofol during 
the month following surgery, but the incidence was not significantly different when propofol was 
compared to xenon (50% vs. 44% at 1 day, 18% vs. 12% at 6 days, and 12% vs. 6% at 30 days, 
respectively).12 Kadoi et al. also examined the effect of propofol and fentanyl on increasing the 
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risk of POCD in a group of 180 older patients after CABG who were randomized to receive 
either propofol or fentanyl.13 All patients received 10 mg of diazepam by mouth one hour before 
anesthesia which was induced by 0.3 mg/kg midazolam, 10 g/kg fentanyl, and 0.2 mg/kg 
vecuronium.13 There was no significant difference in POCD at 6 months between the two groups 
(propofol: 6% vs. fentanyl 7%).13 The results of these studies make it evident that there is still 
conflicting information regarding the association between certain anesthetic/sedative agents and 
the risk of POCD. 
 
2. Home and Perioperative Medications 
 Home medications are any drugs the patient has been taking prior to admission for 
surgery. Perioperative medications are any drugs given to the patient once he has been admitted 
for surgery and until discharge from the post-anesthesia care unit (PACU) after the surgery. The 
main concern is related to medications with anticholinergic or sedative properties that are 
particularly known to be associated with negative cognitive outcomes in older patients.14 The 
age- and disease-associated changes in brain neurochemistry and the way the brain handles such 
medications in older patients make them more likely to develop cognitive impairment than 
younger patients.14 The hypothesis is that the cumulative harmful effects of home medications 
along with those medications being administered during surgery in addition to the anesthetic and 
surgical experience can combine together to insult the brain enough to cause POCD. There is not 
much research that has been done about the use of anticholinergic or sedative medications and 
increased risk of POCD. Most of the research done has been about the relationship between these 
medications and development of POD. However, POD has been associated with POCD and risk 
factors for POD might play a role in the development of POCD.15,16 Recent studies have 
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suggested that the total burden of anticholinergic drugs may determine the development of 
delirium rather than any single agent.14 There are several drugs with anticholinergic 
characteristics that are prescribed with high frequency to patients during and after surgery. 
Examples of these drugs are antihistamines (H1-blockers), antidepressants, antipsychotics, 
antiepileptics, anti-emetics, and muscle relaxants.17 Tune et al. investigated found a significant 
association between serum levels of anticholinergic drugs and POD in patients undergoing 
cardiac surgery.18 Patients with POD had significantly higher serum level of anticholinergic 
drugs (p < 0.001).18 
Benzodiazepines (BDZs) is another group of medications that is frequently prescribed in 
older patients. They are used to manage anxiety and insomnia in the elderly, and even often 
prescribed to manage depressed older adults.19 Many older patients are treated with BDZs for 
prolonged periods, and long-term use of BDZs can accelerate cognitive decline in these 
patients.19 Despite these concerns, epidemiologic data indicate that benzodiazepines are among 
the drugs most commonly prescribed to older adults.20 Among community-dwelling older adults, 
10 – 30% report using a benzodiazepine at any given time, with approximately half of those 
being long-term users.20 There are very few studies that investigated the relationship between 
BDZs and POCD. A study of older patients undergoing cataract surgery found a statistically 
significant relationship between the amount of nitrazepam administered and memory decline 
during the first postoperative week.19  
Another study by Rasmussen et al. hypothesized that diazepam and its active metabolites 
could be detected in blood after abdominal surgery in 35 patient 60 years and older.19 They 
found a POCD incidence of 48.6%, however; the concentration of diazepam or its metabolite 
desmethyldiazepam was not associated with POCD.19 Another study investigated the relationship 
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between POD and duration of BDZs exposure in 328 patients aged 65 to 80 years old who 
underwent orthopedic surgery.21 POD occurred in 26% of BDZs users versus 13% in nonusers (p 
< 0.01) and the incidence was significantly different in long-term BDZs users (daily use for > 1 
year) than short-term users (daily use for < 1 year) [35% vs. 10%, respectively].21  
 
3. Postoperative Medications 
 Postoperative medications are drugs taken by the patient after discharge from the PACU 
and until hospital discharge. Most of the medications administered to the patients at this stage are 
analgesics, especially opioids being the most commonly used medications for postoperative pain. 
They are usually administered either orally, intravenously by a nurse, or through intravenous 
patient-controlled analgesia (PCA). There are reports that the potency of opioids is increased in 
older adults due to their increased peripheral compartment concentration and longer duration of 
action.22 Older patients also increased sensitivity to the effects of BDZs and slower metabolism 
of long-acting agents.23,24 On the other hand, there is a debate that leaving the patient with 
inadequate pain control can put the patient at risk of the same outcomes in addition to 
unnecessary distress, depression, and sleep disturbance.22 Deterioration in sleep can cause 
hyperalgesia which worsens sleep further and increases the need for opioids causing a vicious 
cycle that can have an indirect negative cognitive outcome.22 Few studies have been conducted 
to investigate the relationship between different analgesics, their doses, and route of 
administration and the risk of POCD and POD. 
Marcantonio et al. studied the association between psychoactive medications used 
postoperatively and POD in a case-control study involving 91 patients.25 They found that POD 
was significantly associated with postoperative exposure to meperidine (OR = 2.7; 95% CI = 1.3 
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– 5.5) and to BDZs (OR = 3.0; 95% CI = 1.3 – 6.8).25 There was no significant difference in the 
association between meperidine use and POD whether administered via epidural or PCA.25 They 
also found that long-acting (OR = 5.4; 95% CI = 1.0 - 29.2 vs. 2.6; 1.1 - 6.5) and higher doses of 
BDZ (OR = 3.3; 95% CI = 1.0 - 11.0 vs. 2.6; 0.8 - 9.1) were significantly associated with higher 
risk of POD25. They could not find a statistically significant association between POD and either 
narcotics or anticholinergic drugs.25 Wang et al. conducted a prospective cohort study of 225 
patients 65 years and older undergoing noncardiac surgery and they assessed patients’ cognitive 
function on days one and two after surgery and they found that 13% of patients experienced 
POCD on day one, 7% on day two, and 15% had POCD on either day one or day two after the 
surgery.26 They also found that the only predictive factor for POCD was postoperative analgesia 
with opioids, and that patients who received postoperative analgesia orally were at significantly 
lower risk for the development of POCD (OR = 0.22; 95% CI = 0.06 – 0.80).26 However, this 
study assessed POCD too soon after surgery when the patients were still recovering from 
anesthesia and were under the effect of several medications including sedatives and analgesics. 
There is always the possibility of confusing POCD with POD when assessing POCD too soon 
after surgery like in this study. It is also more important to determine if POCD persists on the 
long-term to confirm that it is not just a temporary condition that occurs during hospitalization of 
the patients then becomes reversible. Vaurio et al. demonstrated a similar association between 
postoperative use of opioids via PCA and increased risk of POD compared with patients who 
used opioids orally.22 These studies show that pain and pain control are important factors to 
consider after surgery especially in older patients who may be at higher risk, and that more 
studies are needed to accumulate enough evidence to guide the pain management practices in this 
population in a way that prevents or minimizes POD and POCD. 
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B. SURGERY 
1. Type of Surgery 
POCD research initially focused on cardiac surgery due to its invasiveness and the 
severity of complications. There was also an assumption that POCD risk may be higher in on-
pump versus off-pump CABG. There was lack of interest in studying POCD after noncardiac 
surgery until Moller et al. conducted the large ISPOCD1 study in a group of 1218 older patients 
and showed that POCD was found in 25.8% of study patients one week after surgery and in 9.9% 
at three months.8 Evered et al. conducted a recent study to determine the association between 
surgery type and incidence of POCD after procedures involving light sedation, general 
anesthesia for noncardiac surgery, and general anesthesia for cardiac surgery involving 
cardiopulmonary bypass.6 The study included three surgical groups (n = 644) [coronary 
angiography (CA) under sedation, major noncardiac surgery (total hip joint replacement [THJR] 
surgery) under general anesthesia, and CABG surgery under general anesthesia) and one non-
surgical control group (n = 34).6 The incidence of POCD one week postoperatively was 17% for 
THJR surgery and 43% for CABG surgery (adjusted OR = 0.2, 95% CI = 0.1 - 0.4; p < 0.01).6 At 
three months, the incidence of POCD was 21% for CA under sedation, 16% for THJR surgery, 
and 16% for CABG surgery.6 The mean difference in proportions of POCD among groups was 
0.00 (-0.07, 0.07) for CABG versus THJR; -0.05 (-0.12, 0.03) for CABG versus CA; and -0.05 (-
0.13, 0.03) for THJR versus CA and there were no significant differences among the three 
groups (adjusted OR = 1.21, 95% CI = 0.94, 1.55; p = 0.13). They concluded that the incidence 
of POCD is independent of the type of surgery.6 There was no significant difference at three 
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months after surgery even between major noncardiac surgery and CABG surgery which is 
hypothesized to be a major risk factor for POCD in cardiac surgery. 
 
2. Intraoperative conditions 
There is a hypothesis that certain irregularities in intraoperative conditions may 
contribute to increasing the risk of POCD. The major four intraoperative variables that have been 
considered in the literature as potential risk factors for POCD are hyperthermia, hypotension, 
hypoxemia, and cerebral embolism. The degree and duration of these conditions also may play a 
role in the severity of POCD. 
Moller et al. conducted a study in 736 patients undergoing major noncardiac surgery with 
general or regional anesthesia to determine if intraoperative monitoring with pulse oximetry to 
reduce the risk of hypoxemia would decrease the incidence of POCD.27 They randomized 
patients to undergo pulse oximetry monitoring (group 1) or not (group 2).27 There was no 
significant difference between the two groups in the incidence of POCD when it was assessed 
one week and three months after surgery.27 In the ISPOCD1 study, Moller et al. assessed the 
incidence of POCD in patients who experienced hypoxemia (defined as one or more episodes of 
oxygen saturation ≤ 80% for > 2 minutes) or hypotension (defined as one or more episodes of 
mean arterial pressure ≤ 60% for ≥ 30 minutes) one week and three months after surgery.8 The 
incidence of POCD was 26% and 11% in patients with hypoxemia and 26% and 9% in patients 
with hypotension, respectively.8 However, they could not find a significant association between 
different degrees and durations of hypoxemia or hypotension and the incidence of POCD after 
one week or three months.8 In some surgical procedures that require dry fields or that are 
associated with substantial blood loss, anesthesia under deliberate hypotensive conditions can be 
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beneficial to the patient, but it can also result in ischemic injury in nonsurgical regions, such as 
the brain and heart.28 William-Russo et al. randomized 235 older adults undergoing total hip 
replacement with epidural anesthesia to one of two levels of intraoperative mean arterial blood 
pressure management (45 – 55 mmHg or 55–70 mmHg).28 There was no significant difference 
between the two groups in the incidence of POCD one week or four months after surgery.28 The 
current few studies in the literature indicate that there is no significant association between 
hypotensive or hypoxemic conditions and the risk of POCD. 
Thromboembolic events may potentially cause cognitive deficits due to ischemic tissue 
damage.4 Rodriguez et al. conducted a study in a convenience sample of 37 patients undergoing 
total knee arthroplasty (TKA) to investigate the relationship between cerebral emboli and the risk 
of POCD at one week and three months after surgery.29 Cerebral emboli occurred in 59.5% of 
study patients and the incidence of POCD was 41% at one week compared to 18% after three 
months.29 However, they could not find a significant association between intraoperative cerebral 
emboli and POCD.29 Liu et al. tried to test the hypothesis that off-pump CABG surgery is 
associated with decreased number of cerebral microemboli and the incidence of POCD.30 They 
included 227 Chinese patients undergoing CABG surgery (59 on-pump vs. 168 off-pump) and 
assessed cognitive function one week and three months after surgery.30 Though, the group with 
off-pump CABG surgery had a significantly decreased number of cerebral microemboli, there 
was no significant difference in the incidence of POCD between the two groups either at one 
week (55.2% vs. 47.0%; p = 0.283, respectively) or three months (6.4% vs. 13.1%; p = 0.214) 
after surgery.30 They also found that neither on-pump surgery nor cerebral microemboli was 
associated with POCD.30 The authors acknowledged some of the limitations of this study such as 
the lack of randomization and potential bias in patient allocation.30 Also, there was a difference 
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in the baseline of one of the cognitive tests in favor of the off-pump group.30 The results of these 
studies show that there is a need for more research in this area to address these limitations and 
accumulate enough evidence to answer the question if cerebral embolism may be a risk factor for 
POCD. 
Only a few non-conclusive studies have been published about the relationship between 
changes in body temperature during surgery especially hyperthermia and the risk of POCD. 
Plourde et al. randomized 62 patients 40 – 70 years old undergoing cardiac surgery to either cold 
or warm CPB (28 °C vs. 36 °C, respectively) and they measured their cognitive function seven 
days postoperatively.31 Only 54 patients completed the study (cold CPB = 24; warm CPB = 
30).31 There was a significant postoperative deterioration in both surgical groups, but no 
differences were observed between groups.31 However, this study was limited by the small 
sample size, absence of a control group to adjust for learning effects from repeated 
administration of the neuropsychological tests, and the assessment of POCD at seven days only 
and not on the long-term.31 Grigore et al. also hypothesized that hypothermic CPB would 
decrease the cognitive deterioration after CABG surgery.32 They recruited 227 patients 
undergoing elective CABG surgery who were randomized to either normothermic (35.5 – 
36.5°C) or hypothermic (28 – 30°C) CPB and they measured cognitive function six weeks after 
surgery.32 There was no difference in cognitive outcomes between normothermic and 
hypothermic groups.32 Salzar et al. randomized 150 patients over 65 years of age who were 
scheduled for total knee replacement to receive standard temperature control (covered with a 
sheet with no active warming) or active warming (infusion of warmed fluids).33 They could not 
find any difference between the two groups in the incidence of POCD three months after the 
surgery (standard care = 14.3%, active warming = 6.5%; p = 0.2440).33 These studies show that 
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there is no evidence yet that body temperature during surgery plays a role in determining the 
incidence of POCD. 
 
3. Neuroinflammation and Brain Injury Biomarkers 
There is a hypothesis that perioperative inflammatory response may be a risk factor for 
POCD in older adults.34 Neuroinflammatory response can result from brain trauma during 
surgery.34 Inflammation during surgery can induce a number of pro-inflammatory cytokines 
leading to a systemic acute-phase response, ‘the illness response’.4 The key cytokines that may 
play a role in the inflammatory process during surgery are interleukin-1 (IL-1), tumor-necrosis 
factor-alpha (TNF-α), IL-6, and IL-8.34,35 The initial reaction is usually the release of IL-1 and 
TNF-α from activated macrophages and monocytes in the damaged tissues.34 This then 
stimulates the production and release of more cytokines, in particular, IL-6, the main cytokine 
responsible for inducing the systemic changes known as the acute phase response.34 
Inflammation has been studied in relation to cognitive deficits in healthy young males and the 
results showed a marked decrease in self-reported level of concentration and cognitive abilities, 
as well as sleep impairment.34 A significant correlation has been found among inflammatory 
markers, C-reactive protein (CRP) and interleukin-1 (IL-1) and neurocognitive decline in cardiac 
surgery.4 Worthy of mention is the hypothesis that neuroinflammation is a common mechanism 
between POCD and Alzheimer’s disease (AD) through the activation of microglial cells which 
have been suggested to be very important for production of inflammatory mediators in response 
to stressors.35,36 Blocking perioperative inflammatory response may play an important role in the 
future in preventing POCD.34 Only a few studies are available in the literature about the 
relationship between inflammatory biomarkers and the risk of POCD. 
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Brain injury markers have also been studied as possible predictors of POCD assuming 
that POCD can be a manifestation of transient or permanent cerebral injury.37 The most 
commonly studied neuronal injury markers in POCD are S-100β protein and neuron-specific 
enolase (NSE) and the results of these studies are still conflicting. Increased blood levels of NSE 
and S-100β protein have been found in patients who sustained clinical neurological 
complications after cardiac surgery.38 There are few studies that have been conducted to evaluate 
the relationship between S-100β and NSE elevation and POCD especially after cardiac surgery. 
Lili et al. tested the neuroinflammation theory in 80 patients 65 years or older undergoing 
abdominal surgery who were randomized to receive ulinastatin (a drug widely used to treat acute 
systemic inflammatory disorders) or to receive regular care in the control group.39 They 
measured cognitive function seven days after surgery and they also measured the level of serum 
IL-6, TNF-alpha, CRP, and S-100β before the surgery, at the end of the surgery, and on 
postoperative days one to three.39 They found that significant decline in cognitive function 
occurred in eight out of the nine cognitive tests they used.39 The ulinastatin group had a lower 
incidence of POCD than the control group (2.5% versus 27.5%; p < 0.05).39 In the control group, 
serum S-100β protein and IL-6 concentrations increased at the end of surgery and on 
postoperative days one and two and the levels were significantly higher than those in the 
ulinastatin group (p < 0.05). This recent study showed that the neuroinflammation theory might 
play a role in the development of POCD and showed the potential for anti-inflammatory drugs to 
protect against POCD in surgery. Also, the study showed that serum elevation of S-100β protein 
can predict POCD. 
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4. Postoperative delirium 
 POD has been generally linked with increased risk of long-term cognitive and functional 
decline.15 POD is usually underestimated after surgery and is subjectively evaluated without the 
use of validated and reliable tools to measure it. There has been much recent interest in studying 
the potential relationship between experiencing POD and increased risk of long-term POCD. 
Rudolph et al. studied a group of 1218 subjects 60 years old or above undergoing elective 
noncardiac surgery and found an association between POD and POCD one week after surgery 
(adjusted risk ratio 1.6, 95% CI: 1.1–2.1), but there was no association between them three 
months after surgery.15 Hudetz et al. conducted a study in male older patients undergoing cardiac 
surgery and included a nonsurgical control group that is similar in age and education level.40 
They also found that POCD incidence was significantly greater in patients who had POD 
delirium (89%) compared with those who did not (37%).40 The odds of developing POCD in 
patients with POD were 14 times greater than in those who did not have POD.40  
 
5. Postoperative Complications 
There is a weak hypothesis that postoperative complications particularly infections and 
respiratory depression may be risk factors for POCD. There are only a few studies that have 
investigated the relationship between POCD and these factors. In the ISPOCD1 study, Moller et 
al. found that postoperative infection and respiratory complications were associated with POCD 
one week after the surgery.8 Further research is needed to prove or refute this theory. Abildstrom 
et al. confirmed that postoperative infections (assessed until three months after surgery) were a 
significant risk factor for POCD one to two years after noncardiac surgery, but they could not 
find an association between respiratory complications and POCD.41  
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C. PATIENT 
1. Age 
Age is the least controversial and strongest independent risk factor for POCD particularly 
when we focus on long-term POCD which is usually assessed at least three months after surgery 
to prevent any confusion with POD. Current POCD research is mainly conducted in older 
patients since the risk of POCD is higher in this population. Moller et al. showed that age was 
associated with both short- and long-term POCD in a group of 1218 older patients aged 60 years 
or older undergoing major noncardiac surgery.8 Monk et al. included 1064 patients aged 18 years 
or older and conducted a stratified analysis by age group and found that age was associated with 
POCD three months after noncardiac surgery.2 The incidence of POCD was 5.7% in young, 
5.6% in middle-aged, and 12.7% in older patients.42 The incidence of POCD was significantly 
higher in older patients compared to their matched controls (p < 0.001).42 Also, Abildstrom et al. 
confirmed that age was a significant risk factor for POCD one to two years after noncardiac 
surgery.41  
 
2. Cognitive Reserve 
Cognitive reserve refers to a patient’s ability to buffer the effects of various insults that 
may occur to the brain during surgery. However, cognitive reserve is subjective and cannot be 
precisely measured, therefore surrogates of cognitive reserve have been suggested to include 
education level, occupational attainment, and performance on tests of knowledge.43 There is 
evidence that greater educational attainment is associated with a reduced relative risk of 
developing Alzheimer's disease and this theory is suggested as one of the factors to be 
considered when discussing the mechanisms and predictors of POCD.43 This theory suggests that 
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patients with higher levels of education, as a hypothetical surrogate of cognitive reserve, may 
have less deterioration in cognitive function than patients with lower education levels when they 
are exposed to an equivalent insult. The association between lower occupational attainment and 
incident dementia has also been discussed in a number of studies.43 In the ISPOCD1 study, 
Moller et al. found that lower education level was associated with higher incidence of early 
POCD at seven days after surgery but not with long-term POCD after three months.8 Monk et al. 
confirmed this finding and also concluded that years of education was associated with POCD 
three months after major noncardiac surgery.42 However, Abildstrom et al. conducted a study in 
336 older patients and followed them for one to two years, but could not find a significant 
relationship between education level and POCD.41 So, it seems that education level plays a role 
in modulating the risk of POCD, but the cognitive reserve concept is probably more complex 
than that and further research of intellectual measurement and its association with POCD is 
needed. 
 
3. Pre-existing Cognitive Impairment Before Surgery 
 Another theory of POCD suggests that patients who have pre-existing cognitive 
impairment before surgery are at higher risk for POCD. This is particularly important to notice in 
some patients with very mild, sometimes unobserved, forms of cognitive impairment who just 
get pushed off of the cognitive cliff by the various stressors during surgery, accelerating their 
cognitive decline and making it more prominent and sometimes permanent. Bekker et al. tested 
this hypothesis when they retrospectively examined the records of 169 community-dwelling 
older patients who were divided into two groups: mild cognitive impairment (MCI) and non-
MCI groups. Patients with MCI had a greater decline in cognitive function than the non-MCI 
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group.44 Silverstein et al. analyzed the data of the ISPOCD1 to determine if there was an 
association between preoperative cognitive impairment (PCI) and POCD.45 They found that the 
incidence of POCD was 19% in patients classified with PCI compared to 26.4% in non-PCI 
patients one week after surgery (p = 0.19).45 At three months, the incidence of POCD was 15% 
in patients classified with PCI compared to 9.5% in non-PCI patients (p = 0.23).45 There was no 
significant association between preoperative cognitive impairment and POCD one week or three 
months after surgery.45 The results of these two studies show that the evidence is still conflicting 
about this theory, and more research is needed to determine if the presence and degree of 
preoperative cognitive impairment can predict POCD. 
 
4. Genetic Biomarkers 
ApoE4 genotype has been implicated as a risk factor for AD, poor outcome after cerebral 
injury, and accelerated cognitive decline with aging.46 There are three different ApoE isoforms 
or alleles (ԑ2, ԑ3, ԑ4). The ApoE4 allele has been associated with increased risk of atherosclerosis 
and AD.47 The link between genetic predisposition with the ApoE4 allele and cognitive decline 
in the aging population is still debatable, since the ApoE4 allele has also been associated with 
cerebrovascular diseases and atherosclerosis which can contribute to cognitive decline.47,48 
Lelis et al. conducted a study in 87 older patients undergoing elective CABG surgery 
who were genotyped for the presence of the ApoE4 allele.49 They found that 21.8% of study 
subjects had POCD and carried the ApoE4 allele.49 They concluded that ApoE4 genotype was 
significantly associated with early POCD one week after surgery (p = 0.04).49 However, this 
study was limited by its small sample size, lack of control group to adjust for learning effects, 
and the use of Mini-Mental State Examination (MMSE) solely to assess cognitive function 
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which is inappropriate, as MMSE is only used to screen for dementia, and the current 
recommendation for POCD assessment is to use a rigorous battery of tests that measures several 
of the following domains: learning and memory, perception and attention, and executive 
functioning.50 Silber et al. could not find an association between ApoeE4 and POCD in 282 
patients undergoing CABG surgery when POCD was assessed three and twelve months after 
surgery.51 The ApoE4 allele was present in 29.4% of total study patients.51 At three months after 
surgery, the incidence of POCD in patients with and without the ApoE4 allele was 7.2% vs. 
12.6% (p = 0.601), respectively.51 At twelve months after surgery, the incidence of POCD in 
patients with and without the ApoE4 allele was 13.3% vs. 11.6% (p = 0.192), respectively.51 
They concluded that POCD was not associated with ApoE4 in patients undergoing CABG 
surgery.51 McDonagh et al. conducted a large study in which they recruited 394 patients over age 
55 years undergoing elective major noncardiac surgery.37 They evaluated the incidence of POCD 
in 350 patients who completed the study and found that the incidence was 54.3% at six weeks 
after surgery and 46.1% at one year.37 There was no difference in the incidence between patients 
with or without the APOE4 allele (56.6 vs. 52.6%; p = 0.58).37 The research about the 
relationship between genetic predisposition with the Apoe4 allele and POCD is very promising, 
however; there is still a need to accumulate enough evidence to confirm this hypothesis.37 
 
5. Comorbidities 
 There is a hypothesis suggesting that certain patient comorbidities, especially endocrine 
and vascular disorders, can contribute to the risk of POCD. This is particularly important to 
study in older patients who usually have multiple comorbidities. Kadoi et al. studied 88 patients 
undergoing elective CABG and they found that the incidence of POCD six months after the 
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surgery was 27.3%.52 There was a significant association between POCD and the presence of 
renal failure (OR = 2.8; 95% CI = 2.4 - 4.3; p < 0.01) and diabetes mellitus (OR = 1.8; 95% CI = 
1.2 - 2.4; p < 0.01) six months after surgery.52 Hudetz et al. studied the association between 
POCD and metabolic syndrome in a group of 60 older patients (30 with metabolic syndrome and 
30 without it) after elective major noncardiac surgery and 30 nonsurgical controls.53 There was a 
significant association between POCD one month after surgery and having the metabolic 
syndrome. Patients with the metabolic syndrome had higher POCD incidence than those without 
it (56.7 vs. 26.7%, respectively).54 There is a dearth of high quality research in this area, but it 
seems that diabetes and vascular diseases could play a role in the risk of POCD. 
 
II. SUMMARY 
The etiology and pathophysiologic mechanisms of POCD are still elusive and POCD is 
likely a multifactorial condition. There are three major theories in the literature that may explain 
POCD: medication, surgery, and patient theories. The variables included in the medication 
theory are type, duration, and depth of anesthesia, the use of highly anticholinergic or sedative 
agents before, during, or after surgery, and the use of certain types of analgesic drugs especially 
opioids postoperatively. The surgery theory suggests that factors associated with higher risk of 
POCD include the type and duration of surgery, undesirable changes in intraoperative conditions 
especially hyperthermia, hypoxemia, and hypotension, exposure of the brain to inflammation or 
traumatic injury during surgery, postoperative delirium, and postoperative complications 
especially infection and respiratory depression. The third theory is focused on the patient and it 
suggests that factors such as older age, less cognitive reserve, pre-existing cognitive impairment 
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before surgery, genetic predisposition with the ApoE4 allele, and patients’ comorbidities 
especially vascular and endocrine diseases may be associated with higher risk of POCD. 
 
III. DISCUSSION 
There remains a gap in the literature about the incidence and risk factors for POCD in 
older adults undergoing major noncardiac surgery. Several studies conducted to date did not use 
enough neuropsychological tests that are sensitive to small changes in cognitive function to 
evaluate POCD. Though there is a concern about the burden of lengthy cognitive testing on the 
patient and the time constraints imposed by the clinical environment to conduct such tests, not 
using enough tests to assess the various domains of cognitive function may result in missing 
important cognitive deficits. Most of the studies did not evaluate patients’ depression and sleep 
quality status before conducting cognitive tests to ensure they did not negatively affect patients’ 
performance on cognitive tests. Many study designs used a single group of patients and 
examined the change in their performance over time without inclusion of a control group, which 
is similar in age and level of education to the surgical group, to adjust for the learning effects that 
occur from repeated administration of neuropsychological tests. This can underestimate the 
incidence of POCD since patients may falsely improve on the tests instead of declining. In 
conclusion, this research area suffers from several methodological issues that need to be 
addressed. There is also a lack of studies evaluating the risk of POCD associated with 
inflammatory biomarkers and genetic predisposition with the ApoE4 allele.  
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CHAPTER 3: SIGNIFICANCE AND SPECIFIC AIMS 
 
I. SIGNIFICANCE 
POCD is not a new phenomenon and many studies have been conducted in this research 
area. However, the incidence and potential risk factors of POCD are still elusive. This is mainly 
due to the discrepancy in the definition of POCD in the literature and the use of measurement 
tools to assess POCD that are not robust. For instance, many studies used the MMSE to 
determine if patients had POCD, though MMSE is only validated for dementia screening and 
should not be used as a neuropsychological tool to diagnose POCD. Also, many studies assessed 
POCD either too early (e.g., one to seven days after surgery) or too late (e.g. one to two years or 
longer after surgery). It is inappropriate to assess POCD too early in the postoperative period as 
it usually gets confused with POD and the residual effects of the anesthesia and sedatives being 
used during the recovery period. Also, assessing POCD too late can result in not being able to 
capture the diagnosis and progress of POCD in the few months following surgery when 
functional and cognitive decline can cause frustration to patients and overall decreased quality of 
life. It is recommended to assess POCD several times after surgery at reasonable intervals (e.g. 
one, three, six, and twelve months) because waiting too long for the first assessment can also 
make it difficult to make the case that observed decline is specifically related to the surgery 
without the interference of other variables such as age-associated memory loss or the progress of 
underlying dementia. 
Only a few studies acknowledged and adjusted for the fact that depression and poor sleep 
quality can negatively affect patients’ performance on neurocognitive tests used for assessment 
of POCD. Most POCD studies focused on patients undergoing cardiac surgery, particularly on-
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pump CABG surgery, and researchers’ attention has just recently shifted to studying POCD after 
major noncardiac surgery. Only a few researchers have investigated the relationship between 
pre-existing cognitive impairment before surgery and the risk of POCD development. Also, few 
studies investigated the potential relationship between genetic predisposition with the ApoE4 
allele or the release of several pro-inflammatory cytokines produced in response to surgical 
stressors and the risk of POCD. Also, there are no studies that investigated the relationship 
between home medications particularly those with highly anticholinergic or sedative effects and 
the risk of POCD. There is a scarcity of studies about the effect of intraoperative conditions 
particularly body temperature, blood pressure, and oxygen saturation and the risk of POCD. 
Lastly but most importantly, many POCD studies did not include a nonsurgical control group to 
adjust for the learning effects from repeated administration of neuropsychological tests which 
can falsely underestimate the incidence of POCD. 
These gaps and limitations of the current literature were the reasons to conduct our 
exploratory study that is intended to determine the incidence and explore the largest number of 
potential risk factors associated with long-term POCD. We used a robust computerized 
neuropsychological battery that is valid, reliable, and sensitive to subtle changes in cognitive 
function. The battery can also assess several important cognitive domains while minimizing 
learning effects by providing alternate forms of the same test, meaning that no two presentations 
of the same test are ever the same. 
The outcomes of this study will help clinicians, patients, and their caregivers make better 
informed decisions before they undergo major noncardiac surgery. With current advances in 
surgery and anesthesia, older patients are less hesitant to undergo surgery, particularly 
noncardiac procedures such as orthopedic or neurosurgery. The study seeks to provide additional 
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evidence to guide these patients and their care providers in assessing the risk-benefit ratio of 
undergoing this type of surgery. It may also help healthcare providers to use the least provocative 
drugs and techniques without losing the benefits of surgery by identifying the risk factors for 
POCD and if some of them may be modifiable. 
  
II. SPECIFIC AIMS 
The specific aims of this study were to: 
a. Determine the incidence of POCD in older adults three months after elective major 
noncardiac surgery. 
b. Identify potential risk factors of POCD in older adults three months after elective 
major noncardiac surgery. 
 
III. SUMMARY 
There is a gap in the literature about the incidence and risk factors of POCD in older 
patients undergoing major noncardiac surgery. The current evidence is either flawed or not 
sufficient to draw definitive conclusions. The specific aims of our study were to determine the 
incidence and risk factors of long-term POCD in older adults undergoing major noncardiac 
surgery. The outcomes of our study should help clinicians, patients, and their care providers 
make better informed decisions when it comes to undergoing this type of surgery understanding 
the incidence of POCD and who might be at risk of experiencing cognitive deterioration after 
surgery. 
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CHAPTER 4: METHODS 
 
This is a prospective cohort study of patients aged 65 years and older who were 
undergoing elective major noncardiac surgery at Virginia Commonwealth University Health 
System (VCUHS). All patients provided written informed consent and the study has been 
approved by VCU Institutional Review Board (IRB). 
 
I. STUDY POPULATION 
Patients were recruited during their visit to the pre-anesthesia clinic at VCUHS. Patients 
had to be able to communicate in English and have the capacity to sign written informed consent. 
Patients were excluded from the study if they were scheduled for another major surgery within 
three months of the study surgery. Patients were also excluded if they scored less than 24 on the 
MMSE-2 standard version during their initial interview. Patients were excluded if they had a 
diagnosis or history of psychiatric disorders (e.g., schizophrenia and bipolar disorders), 
neurodegenerative diseases (e.g., dementia), or metabolic diseases (e.g., diabetes) unless they 
were under the observed care of a physician for the disorder, were taking their prescribed drug 
regimen, and they appeared to the investigator team to be without evidence of cognitive 
problems. Patients were excluded if they had a history of brain tumor or head trauma or if they 
had any kind of motor dysfunction or physical disability (e.g., Parkinson’s disease), or any visual 
or hearing impairment that would preclude computerized neurocognitive testing. 
We also recruited a nonsurgical control group to adjust for the learning effects that may 
occur from repeated administration of neuropsychological tests. The control group was 
constituted of subjects aged 65 years or older recruited from an outpatient geriatric clinic at 
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VCUHS during their regular checkup in addition to eligible individuals who accompanied study 
patients to the pre-anesthesia clinic before surgery and were willing to serve as study controls. 
We also included patients who originally joined the study in the patients group, but their surgery 
was canceled or rescheduled for more than three months later. The control group had the same 
inclusion and exclusion criteria as the study patients except that they were not having any major 
surgery scheduled within three months of their involvement in the study.  
 
II. TYPE OF SURGERY AND ANESTHESIA 
Each study patient received either general anesthesia (inhaled and/or intravenous), 
regional anesthesia (epidural, spinal, and/or nerve block ) with sedation, or a combination of 
general and regional anesthesia based on a collaborative decision among surgeons, anesthesia 
providers and each individual patient as is the current standard practice at VCUHS without any 
influence from the study investigators. 
 
III. OUTCOME ASSESSMENT 
We used a computerized neurocognitive battery called CNS Vital Signs™ (CNSVS) to 
assess cognitive function in both patients and controls. The assessment of cognitive function 
using a computerized battery may be uniquely suited to early detection of cognitive changes in 
the elderly.2 Computerized neurocognitive batteries have the advantages of covering a wider 
range of abilities, minimizing floor and ceiling effects, standardizing the test administration, and 
precisely recording accuracy and speed of response with a level of sensitivity not possible in 
standard administrations with conventional paper-and-pencil testing.2 In addition, they are cost- 
and time-saving compared to conventional neurocognitive tests. They also allow appropriately 
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trained personnel, other than only a neuropsychologist, to be able to administer these tests as 
long as the interpretation of the results is done by the appropriate healthcare professional.2 CNS 
Vital Signs™ neurocognitive battery has high validity and test-retest reliability, and it has been 
evaluated in 1069 volunteers with age range of seven to ninety years old who were in good 
health, without past or present psychiatric or neurological disorders, head injury, learning 
disabilities, etc.; and were not taking any centrally-acting medications.3 Five tests were 
administered to the study patients and controls as described below: 
1. The Verbal Memory test is an adaptation of the Rey Auditory Verbal Learning test.3 
Fifteen words are presented, one by one, and each stays on the screen for two seconds. 
The subject is asked to remember these words, and then a longer list of thirty words is 
presented that contains the first fifteen words the patients was asked to remember in a 
randomly mixed manner. When the subject recognizes a word from the original shorter 
list, he presses the spacebar on the keyboard. After this, the patient continues to complete 
the remaining tests in the battery and just before the end of the testing session (about 20 
minutes later), he is provided with another long list of thirty words that contains the 
original fifteen words in a randomly mixed manner and he is asked again to recognize the 
original fifteen words. 
2. The Visual Memory which is based on the Rey Visual Design Learning test is exactly the 
same as the Verbal Memory test except that fifteen and thirty geometric figures are 
presented to the patient in the original and following lists, respectively, instead of words. 
3. The Symbol Digit Coding test is a variant of the Wechsler Digit Symbol Substitution 
test.3 The subject is given a training session to be familiar with the test before taking the 
actual one. The test consists of serial presentations of screens, each of which contains a 
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bank of eight symbols above and eight empty boxes below.3 The subject types in the 
number that corresponds to the symbol that is highlighted.3 Only the digits from two 
through nine are used to avoid the confusion between “1” and “I” on the keyboard.3 This 
test lasts for 120 seconds and the goal is to type in as many correct numbers as one can in 
this time frame.3 
4. The Stroop Color test is a modification of the Stroop Color Word Interference test and it 
has three parts.3 In the first part, the words RED, YELLOW, BLUE, and GREEN (all 
printed in black) appear at random on the screen, and the subject presses the spacebar as 
soon as he sees the word which generates a simple reaction time score.3 In the second 
part, the words RED, YELLOW, BLUE and GREEN appear on the screen but printed in 
color and the subject is asked to press the spacebar when the color of the word matches 
what the word says.3 In the third part, the words RED, YELLOW, BLUE and GREEN 
appear on the screen, printed in color and the subject is asked to press the spacebar when 
the color of the word does not match what the word says.3 
5. The Shifting-Attention test is based on Trails B and Wisconsin Card Sort test.3 Subjects 
are instructed to match geometric objects either by shape or color.3 Three figures appear 
on the screen, one on the top and two on the bottom.3 The top figure is either a square or a 
circle and the bottom figures are a square and a circle.3 The figures are either red or blue; 
the colors are mixed randomly and the subject is asked to match one of the bottom figures 
to the top figure using a rule that is stated at the top and that keeps randomly changing at 
each presentation (e.g., sometimes it will say ‘match color’ or ‘match’ shape in other 
times).3 This goes on for 90 seconds and the goal is to make as many correct matches as 
one can in the time allotted.3 
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The tests embrace an appropriate span of cognitive domains (composite memory, 
processing speed, executive function, reaction time, and cognitive flexibility) and have been 
shown to be sensitive to most of the causes of mild cognitive impairment.3 The testing time 
required to complete this battery is about 30 minutes. Because the presentation of stimuli in this 
battery is randomized, no two presentations of a specific test are ever the same, making the 
battery appropriate for repeated administration with minimal learning effect. Also, the battery 
provides a brief practice before each test, except for the verbal and visual memory tests, to make 
patients familiar and comfortable with test administration. The personnel who administered the 
battery were extensively trained on neuropsychological test administration and relevant interview 
techniques. Cognitive testing was conducted in a very quiet place and with no distractions to the 
patient at all for the duration of the test. Patients were allowed to take breaks between the tests if 
they felt exhausted, and to ask clarifying questions at any time. 
We compared the level of computer use familiarity between the patient and control 
groups to make sure it did not affect their performance differently on neurocognitive tests. We 
asked subjects in both groups to self-rate their familiarity with general computer use as not 
familiar at all, little familiar, familiar, very familiar, or expert with computer use. We then 
categorized subjects into three groups (not familiar at all, little familiar/familiar, very 
familiar/expert) for the purpose of statistical analysis. 
Patients’ cognitive function was assessed preoperatively and three months after 
postoperatively. We allowed flexibility of two weeks within which cognitive testing had to be 
conducted in order to accommodate for patients’ schedules. Preoperative assessment of cognitive 
function was conducted during patients’ visit to the pre-anesthesia clinic. Postoperative 
assessment of cognitive function was conducted either at the hospital if patients had a follow-up 
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visits three months after surgery, or at patients’ residence if they did not have a follow-up visit 
three months after surgery and they were not willing to come to the hospital for follow-up. The 
same neurocognitive battery was used to assess cognitive function in the study controls at 
baseline (time of recruitment) and three months later allowing flexibility of two weeks within 
which cognitive testing had to be conducted in order to accommodate for controls’ schedules. 
Baseline assessment of cognitive function was conducted during controls’ visit to the outpatient 
geriatric clinic at VCUHS, or at the pre-anesthesia clinic if the control was accompanying a 
study patient. The follow-up testing at three months was conducted either at the hospital or 
residence of the subjects in the control group if they were not willing to come to the hospital for 
follow-up testing. 
 
IV. ASSESSMENT OF POSTOPERATIVE DELIRIUM (POD) 
We evaluated study patients for the presence of POD 48 hours after their surgery while 
they were still in the hospital. Our goal was to determine if patients who experienced POD after 
postoperatively were more likely to experience POCD three months after surgery. We used the 
Confusion Assessment Method (CAM) for this purpose.4 This test has been validated and it has 
high sensitivity (94 – 100%) and specificity (90 – 95%) for detection of delirium.4 It is also 
relatively easy and quick to administer, as it takes only five to ten minutes to complete. 
 
V. DEPRESSION AND SLEEP QUALITY TESTING 
It is well known that several factors including depression and poor sleep quality may 
have a negative impact on a subject’s motivation, and can adversely affect his performance on 
neuropsychological tests.5,6 For this reason, we evaluated our study subjects for the possibility of 
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having depression and poor sleep quality before each cognitive testing session using the Geriatric 
Depression Scale - Short-Form (GDS-SF) and the Pittsburgh Sleep Quality Index (PSQI), 
respectively. The GDS-SF is composed of 15 yes/no questions and it has been compared to the 
long-form 30 yes/no questions and showed to have equivalent sensitivity and specificity in older 
adults.7  A score of 5 - 10 on the GDS-SF is suggestive of mild depression and a score of 11 - 15 
is suggestive of severe depression. The PSQI takes about five minutes to administer and provides 
a highly valid, reliable, and standardized measure of sleep quality for the previous month.8 It also 
provides an index that is easy for researchers and clinicians to interpret and compare among 
different patients.8 In patients with primary insomnia, PSQI has shown a test-retest reliability of 
0.87, sensitivity of 89.6 – 98.7, and specificity of 84.4 – 86.5.8,9 A score of more than five on the 
PSQI is suggestive of poor sleep quality, and the higher the score, the poorer patient’s sleep 
quality is. 
Our goal was to make sure we are only evaluating the change in cognitive function before 
and three months after surgery in the surgical group with minimal or no interference from other 
factors that could affect performance of study subjects on cognitive tests. First, we tested if there 
was any significant change in the depression and sleep quality test scores from baseline till 
follow-up within each study group, which could affect the performance of any of the two groups 
differently on neurocognitive tests. Second, we compared the depression and sleep quality test 
scores between the patient and control groups at baseline and follow-up to determine if there was 
a difference between the two groups in depression status or sleep quality that could affect their 
performance differently on neurocognitive tests.  
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VI. DATA COLLECTION 
Patients’ demographics, medical history, medication use, level of education, and 
computer familiarity were documented before surgery by questioning the patients and reviewing 
their medical charts. During the surgery, we collected information about the type, and duration of 
anesthesia used. We also documented the type of surgery and the incidence of intraoperative 
hypothermia, hypotension, and hypoxemia. For the purpose of this study, based on the views of 
the anesthesia clinicians and surgeons involved in the study, we operationalized the definitions of 
hypothermic, hypotensive, and hypoxemic events. A hypotensive event was defined as mean 
blood pressure that is 20% lower than baseline. A hypothermic event was defined as body 
temperature equal to or less than 36 ºC. A hypoxemic events was defined as oxygen saturation 
less than 90%. After the surgery, we documented all postoperative medications taken by the 
patient and any complications the patient may have experienced until hospital discharge. Study 
data were collected and managed using the Research Electronic Data Capture (REDCap™) tool 
hosted at VCU.1 REDCap™ is a secure, web-based application designed to support data capture 
for research studies. Figure 1 summarizes the data collection process throughout the study from 
baseline to follow-up. 
 
VII. APOE GENOTYPING 
On the day of surgery, we collected a 5-ml blood sample in a purple-top vacutainer just 
before the induction of anesthesia from patients who opted to do this optional part of the study. 
The sample was stored at -80 ºC until DNA purification has been done using the Spin-Column 
protocol (DNeasy® Blood Kit, QIAGEN®). A 10 µl of diluted DNA per sample was transferred 
into a 96-well plate. The DNA plate was placed into a thermal cycler and heated to 95 ºC for 5 
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minutes. Once the heating process was completed, the DNA plate was placed on ice. DNA 
amplification was performed using Taq polymerase kit (cat no. 18038-240, Invitrogen™). The 
PCR product was checked on a 1% agarose gel electrophoresis. Restriction length fragment 
polymorphism digestion was done by Hhal restriction enzyme. At the end of the incubation, the 
reactions were terminated by the addition of bromophenol blue dye. The samples were then 
loaded onto polyacrylamide gels. DNA ladder was added as reference and electrophoresis was 
run. The gel was then soaked in a solution of ethidium bromide and viewed under UV light.  A 
computer-generated picture of the gel was recorded. Two independent researchers reviewed the 
gel images and assigned an APOE genotype based on appropriate banding. 
 
Figure 1. Summary of Data Collection Process from Baseline to Follow-up 
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VIII. INFLAMMATORY BIOMARKER ANALYSIS 
On the day of surgery, we collected a 5-ml blood sample in a gold-top vacutainer just 
before the induction of anesthesia from patients, who opted to do this optional part of the study, 
to determine the preoperative level of CRP and evaluate if patients with preoperative heightened 
inflammatory response may be at higher risk for POCD. The blood sample was allowed to clot 
for 30 minutes after collection then it was centrifuged at 3500 RPM for 10 minutes at 4 ºC. The 
CRP analysis was done on the serum using the polyethylene glycol (PEG) enhanced 
immunoturbidimetric assay on Advia® 1800 analyzer.10 The method uses PEG to accelerate the 
antigen-antibody interaction. The sample was allowed to react with a specific antiserum to form 
a precipitate that was measured turbidimetrically at 340/694 nm. By constructing a standard 
curve from the absorbances of standards, concentrations were determined. The reference range 
for CRP level is 0.0 – 0.5 mg/dL and any value above that was considered high. The limit of 
quantification for the test was 0.3 – 32.0 mg/dL. Estimates of precision, based on Clinical and 
Laboratory Standards Institute (CLSI) recommendations, are consistent with typical 
performance. The within run precision is less than 5% coefficient of variation (CV) and the 
standard deviation (SD) is equal to or less than 1, and the total precision is less than 5% CV and 
SD is equal to or less than 1. 
 
IX. STATISTICAL ANALYSIS 
Descriptive analysis of patients’ demographics, education level, computer familiarity, and 
baseline MMSE-2 score was conducted. Continuous data were reported as mean and standard 
deviation and/or range, and were compared using t-test or analysis of variance (ANOVA). 
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Proportions were given as numbers and percentages were compared using Chi-square (2) or 
Fischer’s exact test, when applicable. 
The scores of GDS-SF and PSQI were compared at baseline and three months later 
within each of the patient and control groups using paired t-test to determine if there has been 
any significant change in depression status or sleep quality from baseline to follow-up that could 
have affected their performance differently on cognitive tests. Next, the scores of depression and 
sleep quality tests were compared between the two groups at baseline and follow-up using 
ANOVA to determine if there was a significant difference between the two groups in their at 
baseline or follow-up that could have interfered with their performance on cognitive tests. 
 
A. Specific Aim #1 
Determination of the incidence of POCD was done using the Z-Score method that was 
originally used in both the ISPOCD1 and ISPOCD2 studies.11,12 A nonsurgical control group, that 
is similar to the patients’ group in age, education level, and computer familiarity, was recruited 
to adjust for potential learning or practice effects that may occur from repeated administration of 
the cognitive tests. An individual Z-score was calculated for each test for each subject in the 
surgical group by subtracting the mean score change for each test in the control group from the 
score change in each patient in the surgical group from baseline to follow-up. The result was 
then divided by the standard deviation for the mean score change in the control group. A 
composite Z-score was also calculated by adding all individual Z-scores and dividing them by the 
standard deviation of the mean sum of Z-scores in the control group. A patient was classified as 
having POCD if he had an individual Z-score of less than -1.96 in two or more cognitive tests or 
a composite Z-score of less than -1.96. This technique identifies patients with POCD by 
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comparing the changes in test scores of an individual patient undergoing surgery with changes in 
the test scores of the comparable control group over the same time interval.13 
 
B. Specific Aim #2 
A series of univariable logistic regression analyses using Chi-square were conducted at a 
less conservative significance level of 0.25 to allow for the selection of potential predictors of 
POCD without risking excluding some important variables that might play a role in the risk of 
POCD in the final model. The univariable analysis included potential predictors of POCD from 
the patient, surgery, and medication theories. The patient variables included age (65 – 74 years 
old, 75 or older), gender (male, female), race (White, African-American or other), education 
level (high school or less, more than high school), computer familiarity (not familiar at all, little 
familiar or familiar, very familiar or expert), vascular and endocrine comorbidities (diabetes, 
hypertension, hypothyroidism, hypercholesterolemia), and ApoE genotype (ApoE4, non-
ApoE4). The surgical variables included type of surgery (orthopedic surgery, neurosurgery), type 
of anesthesia [general (inhaled, intravenous), regional (epidural, spinal, nerve block), a 
combination of general and regional], duration of anesthesia (less than three hours, three hours or 
more), use of nitrous oxide for general anesthesia (yes, no), use of desflurane for general 
anesthesia (yes, no), use of sevoflurane for general anesthesia (yes, no), preoperative level of 
CRP (normal or low, high), postoperative delirium (yes, no), hypotensive events (yes, no), 
hypoxemic events (yes, no), and hypothermic events (yes, no). The medication variables 
included the use of highly anticholinergic or sedative-hypnotic medications at home and 
postoperatively (nonusers, users of one or more medications). The medication selection was 
based on potential cognitive adverse outcomes of these medications in older adults as 
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documented in the American Geriatrics Society 2012 updated Beers criteria for potentially 
inappropriate medication use in older adults.14 We also evaluated the use of morphine (IV and 
PCA), hydromorphone (IV and PCA), and oxycodone as postoperative analgesics (users, 
nonusers) to determine if they were risk factors for POCD. 
The model building process was done using backward stepwise logistic regression (p-
value was set at 0.25 and 0.10 for entering and leaving the model, respectively). The use of 
backward stepwise regression was preferred due to the exploratory nature of our study and the 
lack of definite knowledge of the potential predictors of POCD. Backward stepwise regression 
begins with a model that includes all potential candidate variables of interest and minimizes the 
risk of an important predictor not entering the model if the forward selection method was used. 
Starting with all predictors, backward stepwise has the opportunity to identify and account for 
any suppressor relationship among variables that can be found in the data. However, the 
backward stepwise method has the disadvantage that it capitalizes on chance and the presence of 
a large number of variables at once can lead to too many comparisons that may increase the risk 
of ‘noise’ variables being included, which can decrease the predictive power of the model. 
Results of the logistic regression analysis were reported as adjusted OR and 95% CI for 
each variable in the multivariable logistic model using Firth’s method to accommodate for the 
rarity of outcome and small sample size in our study. In normal logistic regression using the 
maximum likelihood estimation method, we need at least five to ten events/outcomes in the 
group with the smaller number of events for each predictor to be tested in the model. Firth’ 
method uses penalized maximum likelihood estimation method to reduce biased estimation in 
case of rare events like in our study allowing us to relax the criteria of five to ten events per 
tested predictor. We considered p-values less than 0.05 to be statistically significant, and p-
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values were two-sided for all statistical tests, when applicable. Data analysis was performed 
using JMP® Pro 10.0.2 (SAS® Institute Inc., Cary, NC).  
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CHAPTER 5: RESULTS 
 
I. DEMOGRAPHICS AND BASELINE CHARACTERISTICS OF STUDY SUBJECTS 
A total of 130 patients (surgical group) and 103 controls (nonsurgical group) were 
approached for possible inclusion in the study, from which 96 patients and 93 controls consented 
to participate in the study. After applying the inclusion and exclusion criteria and eliminating 
those who were lost to follow-up, a total of 69 surgical and 54 nonsurgical were included in the 
study and final analysis. Figures 1 and 2 show the recruitment process for the surgical and 
nonsurgical groups, respectively. 
The mean age for the surgical group was 71 years old and it ranged from 65 – 88 years 
old. The mean age for the nonsurgical group was 73 years old and it ranged from 65 – 92. There 
was a marginal difference between the two groups in age (p = 0.0428). White patients constituted 
81.2% of the surgical group and 14.5% were African-American. In the nonsurgical group, 51.9% 
were White and 48.1% were African-American. There was a difference between the two groups 
in race (p < 0.0001). Females constituted 66.7% in the surgical group compared to 64.8% in the 
nonsurgical group. There was no difference between the two groups in gender (p = 0.8298). The 
two groups had similar education level (p = 0.1085), and most of the subjects in both groups had 
an education level above high school (78.3% of surgical and 64.8% of nonsurgical study 
subjects). There was no difference between the two groups in computer familiarity (p = 0.6821). 
There was also no difference between the two groups in their baseline MMSE-2 score (p = 
0.1235). Table 1 summarizes the demographics and baseline characteristics of both surgical and 
nonsurgical groups. 
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Figure 1. Recruitment Process for the Study Surgical Group 
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Figure 2. Recruitment Process for the Study Nonsurgical Group 
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Table 1. Demographics and Baseline Characteristics of Surgical and Nonsurgical Groups 
 
Variable Surgical 
(N = 69) 
Nonsurgical 
(N = 54) 
p-value 
Age ± SD (range) 71 ± 5.4 (65 - 88) 73 ± 6.3 (65 - 92) 0.0428* 
Gender (Females), % 46 (66.7%) 35 (64.8%) 0.8298 
Race, %   <0.0001* 
White 56 (81.2%) 28 (51.9%)  
African-American 10 (14.5%) 26 (48.1%)  
Other 3 (4.3%) 0 (0.0%)  
Education Level, %   0.1085 
High school or less 15 (21.7%) 19 (35.2%)  
More than high school 54 (78.3%) 35 (64.8%)  
Computer Familiarity, %   0.6821 
Not familiar at all 9 (13%) 10 (18.5%)  
Little familiar or familiar 37 (53.6%) 26 (48.1%)  
Very familiar or expert 23 (33.3%) 18 (33.3%)  
MMSE-2 Score ± SD 28 ± 1.4 28 ± 1.7 0.1235 
*p-value < 0.05 
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II. DEPRESSION STATUS AND SLEEP QUALITY AT BASELINE AND FOLLOW-UP 
First, we compared the depression status and sleep quality score change from baseline to 
follow-up within each of the surgical and nonsurgical groups using paired t-test to determine if 
there has been any change in depression or sleep quality within each group from baseline to 
follow-up. We wanted to rule out the possibility that a change in depression status or sleep 
quality within any of the two groups could have affected that group’s performance on 
neurocognitive tests differently from baseline to follow-up. Table 2 summarizes the mean and 
follow-up depression scores and the differences in these scores between the two testing sessions 
within each group. There was no difference in depression status between the two testing sessions 
within the surgical or nonsurgical group (t = 0.67, p = 0.51; t = -0.99, p = 0.33, respectively). 
Table 3 summarizes the mean and follow-up sleep quality scores and the differences experienced 
in these scores from baseline to follow-up within each group. There was no difference in sleep 
quality from baseline to follow-up within the surgical or nonsurgical group (t = 0.57, p = 0.57; t 
= 0.21, p = 0.83, respectively). These results show that there was no significant change in 
depression status or sleep quality within the surgical or nonsurgical groups that could have 
affected their performance on cognitive testing at baseline and the three-month follow-up. 
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Table 2. Comparison of Depression Status scores within Surgical and Nonsurgical Groups at 
Baseline and Three-Month Follow-up as Measured by GDS-SF 
 
Group Time N Mean 
Score
SD Lower 
95% CI
Upper 
95% CI 
Surgical 
Baseline 69 2.1 2.2 1.5 2.6 
Follow-up 69 2.2 2.6 1.6 2.8 
Difference 69 0.1 1.8 -0.3 0.6 
Nonsurgical 
Baseline 54 2.6 2.7 1.9 3.3 
Follow-up 54 2.3 2.9 1.5 3.1 
Difference 54 -0.3 2.2 -0.9 0.3 
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Table 3. Comparison of Sleep Quality within Surgical and Nonsurgical Groups at Baseline and 
Three-Month Follow-up as Measured by PSQI 
 
Group Time N Mean 
Score
SD Lower 
95% CI
Upper 
95% CI 
Surgical 
Baseline 69 6.8 3.7 5.9 7.7 
Follow-up 69 7.0 3.8 6.1 7.9 
Difference 69 0.2 3.0 -0.5 0.9 
Nonsurgical 
Baseline 54 6.3 4.0 5.2 7.4 
Follow-up 54 6.4 3.9 5.3 7.4 
Difference 54 0.1 2.6 -0.6 0.8 
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Second, we compared depression status and sleep quality scores between the surgical and 
nonsurgical groups at baseline and follow-up using ANOVA to determine if they were different 
in depression status or sleep quality at baseline or follow-up. Table 4 summarizes the mean 
GDS-SF scores for both the surgical and nonsurgical groups at baseline and follow-up. ANOVA 
test showed no difference in depression status between the two groups at baseline (F (1, 121) = 
1.37, p = 0.2447) or after three months (F (1, 121) = 0.03, p = 0.8738). Table 5 summarizes the 
mean PSQI scores for both the surgical and nonsurgical groups at baseline and follow-up. 
ANOVA test showed no difference in sleep quality scores between the two groups at baseline (F 
(1, 121) = 0.45, p = 0.5059) or after three months (F (1, 121) = 0.73, p = 0.3954). These results 
show that there was no significant difference in depression status or sleep quality between the 
surgical or nonsurgical groups at either baseline or follow-up that could have affected their 
performance differently on cognitive testing. 
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Table 4. Comparison of Depression Status between Surgical and Nonsurgical at Baseline and 
Follow-up as Measured by GDS-SF 
 
Time Group N Mean 
Score
SD Lower 
95% CI
Upper 
95% CI 
Baseline 
Surgical 69 2.1 2.2 1.5 2.7 
Nonsurgical 54 2.6 2.7 1.9 3.3 
Follow-up 
Surgical 69 2.2 2.6 1.6 2.9 
Nonsurgical 54 2.3 2.9 1.6 3.0 
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Table 5. Comparison of Sleep Quality between Surgical and Nonsurgical at Baseline and Follow-
up as Measured by PSQI 
 
Time Group N Mean 
Score
SD Lower 
95% CI
Upper 
95% CI 
Baseline 
Surgical 69 6.8 3.7 5.9 7.7 
Nonsurgical 54 6.3 4.0 5.3 7.4 
Follow-up 
Surgical 69 7.0 3.8 6.1 7.9 
Nonsurgical 54 6.4 3.9 5.4 7.4 
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III. INCIDENCE AND RISK FACTORS OF POCD 
A patient in the surgical group was classified as having POCD if he had an individual Z-
score of less than -1.96 in two or more of the cognitive tests, or a composite Z-score of less than -
1.96. Based on this method, a total of 11 (15.9%) patients in the surgical group were classified as 
having POCD. We evaluated the association between POCD and several variables at a preset 
significance level of 0.25 to screen for potential predictors of POCD to be entered into the final 
logistic regression model with a significance level of 0.05. We chose the stepwise backward 
logistic regression method to build the model due to the exploratory nature of this study and lack 
of a specific hypothesis. Table 6 shows the results of the univariable analysis of potential risk 
factors for POCD and the distribution of patients with POCD across the levels of each predictor. 
Only one patient did not opt to provide blood samples for the purpose of CRP and ApoE4 
analysis, which was an optional part of the study that patients could opt out of it. Among the 
patients who were using anticholinergic drugs before surgery, four were using diphenhydramine, 
four were using loratadine, three were using meclizine, two were using promethazine, one was 
using cyclobenzaprine, one was using methocarbamol, one was using tizanidine, one was using 
solifenacin, and one was using scopolamine. Among the patients who were using sedative-
hypnotic drugs before surgery, six were using zolpidem, three were using clonazepam, two were 
using diazepam, two were using alprazolam, one was using lorazepam, and one was using 
flurazepam. 
In the surgical group, 13 patients received general anesthesia and 48 received regional 
anesthesia, and eight patients received combined general and regional anesthesia. Among those 
who received general anesthesia, 20 patients received sevoflurane, two patients received 
sevoflurane, and seven patients received nitrous oxide. 
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Table 6. Results of Univariable Analysis for Initial Screening of Potential Risk Factors for POCD 
 
Variable N = 69 POCD No POCD p-value
Age     
65 – 74 years old 55 10 (18.2%) 45 (81.8%) 0.4397 
≥ 75 years old 14 1 (7.1%) 1 (92.9%)  
Gender     
Male 23 2 (8.7%) 21 (91.3%) 0.3139 
Female 46 9 (19.6%) 37 (80.4%)  
Race     
White 56 9 (16.1%) 47 (83.9%) 1.000 
African-American or other 13 2 (15.4%) 11 (84.6%)  
Education Level     
High school or less 15 4 (26.7%) 11 (7.3%) 0.2374 
More than high school 54 7 (13.0%) 47 (87.0%)  
Computer Familiarity     
Not familiar at all 9 1 (11.1%) 8 (88.9%) 1.000 
Little familiar or familiar 37 6 (16.2%) 31 (83.8%)  
Very familiar or expert 23 4 (17.4%) 19 (82.6%)  
Diabetes     
No 57 9 (15.8%) 48 (84.2%) 1.000 
Yes 12 2 (16.7%) 10 (83.3%)  
Hypertension     
No 31 6 (19.4%) 25 (80.6%) 0.5251 
Yes 38 5 (13.2%) 33 (86.8%)  
Hypothyroidism     
No 64 10 (15.6%) 54 (84.4%) 1.000 
Yes 5 1 (20.0%) 4 (80.0%)  
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Hypercholesterolemia     
No 57 9 (15.8%) 48 (84.2%) 1.000 
Yes 12 2 (16.7%) 10 (83.3%)  
ApoE4 Genotype#     
Non-ApoE4 54 6 (11.1%) 48 (88.9%) 0.0407 
ApoE4 14 5 (35.7%) 9 (64.3%)  
Type of Surgery     
Orthopedic Surgery 61 8 (13.1%) 53 (86.9%) 0.1090 
Neurosurgery 8 3 (37.5%) 5 (62.5%)  
Type of Anesthesia     
General anesthesia 13 3 (23.1%) 10 (76.9%) 0.0091 
Regional anesthesia 48 4 (8.3%) 44 (91.7%)  
Combined general and regional anesthesia 8 4 (50.0%) 4 (50.0%)  
Duration of Anesthesia     
Less than three hours 23 6 (26.1%) 17 (73.9%) 0.1611 
Three or more hours 46 5 (10.9%) 41 (89.1%)  
Use of Nitrous Oxide for General Anesthesia     
No 62 8 (12.9%) 54 (87.1%) 0.0751 
Yes 7 3 (42.9%) 4 (57.1%)  
Use of Desflurane for General Anesthesia     
No 67 10 (14.9%) 57 (85.1%) 0.2954 
Yes 2 1 (50.0%) 1 (50.0%)  
Use of Sevoflurane for General Anesthesia     
No 49 5 (10.2%) 44 (89.8%) 0.0669 
Yes 20 6 (30.0%) 14 (70.0%)  
CRP Level#     
Normal or low 50 7 (14.0%) 43 (86.0%) 0.7175 
High 18 3 (16.7%) 15 (83.3%)  
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Postoperative Delirium^     
No 44 5 (11.4%) 39 (88.6%) 0.6014 
Yes 10 2 (20.0%) 8 (80.0%)  
Hypotensive Events     
No 7 1 (14.3%) 6 (85.7%) 1.000 
Yes 62 10 (16.1%) 52 (83.9%)  
Hypoxemic Events     
No 63 11 (17.5%) 52 (82.5%) 0.5795 
Yes 6 0 (0.0%) 6 (100.0%)  
Hypothermic Events     
No 10 3 (30.0%) 7 (70.0%) 0.1920 
Yes 59 8 (13.6%) 51 (86.4%)  
Use of ≥ 1 Anticholinergic or Sedative-Hypnotic 
Drugs at Home Prior to Surgery 
    
Nonusers 44 4 (9.1%) 40 (90.9%) 0.0830 
Users 25 7 (28.0%) 18 (72.0%)  
Use of ≥ 1 Anticholinergic or Sedative-Hypnotic 
Drugs after Surgery 
    
Nonusers 37 4 (10.8%) 33 (89.2%) 0.2106 
Users 32 7 (21.9%) 25 (78.1%)  
Use of Morphine for Postoperative Pain     
No 66 9 (13.6%) 57 (86.4%) 0.0640 
Yes 3 2 (66.7%) 1 (33.7%)  
Use of Hydromorphone for Postoperative Pain     
No 29 5 (17.2%) 24 (82.8%) 1.000 
Yes 40 6 (15.0%) 34 (85.0%)  
Use of Oxycodone for Postoperative Pain     
No 14 3 (21.4%) 11 (78.6%) 0.6827 
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Yes 55 8 (14.6%) 47 (85.4%)  
*p-value < 0.25 
#One patient refused to provide blood samples for testing of genetic and inflammatory biomarkers 
^Fifteen patients were discharged earlier than the time for assessment of postoperative delirium 
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The variables that were included in the final model were ApoE4 genotype, use of one or 
more highly anticholinergic or sedative-hypnotic medications at home, and the use of 
sevoflurane for anesthesia. There was no evidence of lack of fit of the final model for the 
included variables which was tested using Hosmer-Lemeshow goodness-of-fit test (p = 0.9550). 
Table 6 presents the results of the multivariable logistic regression analysis with adjusted OR, 
95% CI, and p-values for the predictors that were entered in the final model and also the 
incidence of POCD at different levels of each variable. 
 The association of ApoE4 genotype with POCD was such that patients in the surgical 
group who had the ApoE4 gene were more likely to have POCD three months after the surgery 
as compared to patients who did not have the ApoE4 gene (OR = 4.74, 95% CI = 1.09 – 22.19, p 
= 0.0371). Patients in the surgical group who were using one or more highly anticholinergic or 
sedative-hypnotic drugs at home before surgery were more likely to have POCD three months 
after the surgery when compared to patients who were not taking any drug with high 
anticholinergic or sedative-hypnotic characteristics (OR = 5.64, 95% CI = 1.35 – 30.22, p = 
0.0137). Patients who were administered sevoflurane for anesthesia were more likely to have 
POCD three months after surgery than patients who did not receive it (OR = 6.43, 95% CI = 1.49 
– 34.66, p = 0.0102). 
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Table 7. Results of Multivariable Logistic Regression showing Factors Associated with POCD 
 
Variable N POCD No POCD Adjusted OR 
(95% CI) 
p-value 
ApoE4 Genotype      
Non-ApoE4 54 6 (11.1%) 48 (88.9%) 1.00 0.0371* 
ApoE4 14 5 (35.7%) 9 (64.3%) 4.74 (1.09 – 22.19)  
Use of ≥ 1 Anticholinergic/Sedative-Hypnotic 
Drugs at Home Prior to Surgery 
     
Nonusers 44 4 (9.1%) 40 (90.9%) 1.00 0.0137* 
Users 25 7 (28.0%) 18 (72.0%) 5.64 (1.35 – 30.22)  
Use of Sevoflurane for Anesthesia      
No 49 5 (10.2%) 44 (89.8%) 1.00 0.0102* 
Yes 20 6 (30.0%) 14 (70.0%) 6.43 (1.49 – 34.66)  
*p-value < 0.05 
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IV. SUMMARY 
The study included 69 patients aged 65 years and older who underwent elective major 
noncardiac surgery (orthopedic surgery and neurosurgery) and 54 nonsurgical controls to adjust 
for the learning effects from repeated administration of the neurocognitive tests. The surgical and 
nonsurgical groups were similar in gender, education level, computer use familiarity, and 
baseline MMSE-2 score. The two groups were different in age marginally in favor of the 
nonsurgical group, and in race as the surgical group had larger proportion of White subjects. 
There was no difference between the two groups in depression status and sleep quality scores at 
baseline or follow-up. Within each group, there was no difference in depression status and sleep 
quality scores between baseline and follow-up. Using the Z-score method, we identified 11 
(15.9%) patients with POCD in the surgical group. Multivariable logistic regression analysis 
using Firth’s method showed that carrying the ApoE4 allele (at least one allele), using one or 
more highly anticholinergic or sedative-hypnotic medications at home prior to surgery, and 
receiving sevoflurane for anesthesia were predictors of the development of POCD. 
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CHAPTER 6: DISCUSSION 
 
I. INCIDENCE OF POCD 
The results of this study showed that about 16% of study subjects were identified with 
POCD three months after elective major noncardiac surgery. A major difficulty of all POCD 
studies is the comparability of POCD incidence between different studies, as this depends largely 
on how POCD was defined and what was considered as ‘sufficient’ decline in cognitive function 
after surgery in each study. Also, this varies by the time of postoperative assessment of cognitive 
function. Several studies overestimated the incidence of POCD by evaluating it during the first 
week after surgery when the patient is still having pain, in recovery from anesthesia, and under 
the influence of several postoperative analgesics. The incidence will also depends on whether the 
study has a control group to adjust for learning effects that occur from repeated administration of 
neurocognitive tests. 
In our study, we used the most stringent definition of POCD that is dependent on the Z-
score method originally used by the ISPOCD group, and we also used a control group to adjust 
for learning effects.1 However, the use of POCD as a dichotomous variable (yes or no) has its 
limitations as well particularly it decreases the power of the study as compared to defining it as a 
continuous variable by assessing mean score change in study subjects. However, the use of mean 
score change in POCD studies is not recommended because learning effects are disregarded, and 
the individual change is thereby not assessed. Instead, the definition of POCD should be based 
on comparing preoperative with postoperative test results for each patient. The Z-score method 
provides us with information about the expected improvement over time in the surgical group by 
looking at the change in the nonsurgical control group. This definition corrects for this learning 
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effect and eliminates the risk that a true deterioration in cognitive function may be overlooked in 
the surgical group. 
Newman et al. conducted a meta-analysis of POCD studies in noncardiac surgery until 
December 2005 showing that the incidence of POCD was 6.2% - 56% after major noncardiac 
surgery when assessed 22 days and up to six months after surgery.2 When ignoring one of the 
studies included in the meta-analysis with unexpectedly very high incidence, the incidence of 
POCD was between 6.2% - 9.4%.2 The incidence of POCD in our study is in agreement with the 
incidence reported in the first ISPOCD study which was about 10%.1 Monk et al. conducted a 
study in 1064 patients, 308 of which were in a group aged 60 years or older.3 Three months after 
surgery, the incidence of POCD was 12.7% in this group of older patients, which is comparable 
to the percentage of POCD in our study.3 Koch et al. reported a POCD incidence of 45% three 
months after surgery in a group of 24 patients aged 65 years or older who underwent elective 
knee or hip replacement.4 The incidence reported in this study is very high compared to our 
study. However, though this study used robust measures for neuropsychological testing, their 
definition of POCD was very arbitrary and is not the currently acceptable definition in POCD 
research that was established by the first ISPOCD study. Koch et al. used a definition of at least 
20% decline from baseline in two or more tests which could result in the overestimated incidence 
of POCD. Evered et al. conducted a very recent study in 644 patients, 157 of which were 55 
years and older, who underwent total hip joint replacement.5 They reported a POCD incidence of 
16% three months after surgery which is also in agreement of the incidence in our study.5 Deo et 
al. conducted a study in two groups of patients undergoing knee replacement with age ranging 
from 43 to 82 years old, and they compared the incidence of POCD in the two groups using two 
different surgery techniques.6 They found a similar POCD incidence of about 30% six months 
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after surgery in both groups.6 This high incidence of POCD in this study may be also be a result 
of using a less stringent approach in diagnosing POCD (0.5 SD decline in at least three cognitive 
tests).6 
Our study used a robust computerized neurocognitive battery that is valid and reliable, 
and is designed specifically to evaluate subtle changes in cognitive function over time. The 
battery measures several cognitive domains that were recommended by consensus guidelines for 
evaluation of POCD.7 The battery was also validated in volunteers with several age groups 
ranging from seven to ninety years old, which includes the age range for our study patients.8  We 
used a control group that is similar to the surgical patients in age, education level, and computer 
use familiarity along with the use of parallel forms in the neurocognitive battery to prevent or 
minimize learning effects to the most degree possible. In addition to that, we used the currently 
established Z-score method for identifying patients with POCD. This definition that was 
originally used in the first ISPOCD study is robust and it also adjusts for any learning effects 
from repeated administration of the cognitive tests to provide a reasonably accurate estimate of 
POCD incidence. 
It is also very important to note that we acknowledged the fact that depression and poor 
sleep quality can negatively affect performance on neuropsychological testing, and we evaluated 
the depression status and sleep quality for the surgical and nonsurgical groups at baseline and 
follow-up to make sure there was no variability in depression status or sleep quality within and 
between the two groups that could have affected their performance differently on cognitive tests, 
and consequently the incidence of POCD. Our decision to evaluate the incidence of POCD three 
months after surgery was based on the overestimated incidence observed in several studies that 
evaluated POCD too soon after surgery and reported an inflated incidence of POCD. Even if a 
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the high incidence of POCD reported in some studies shortly after surgery represents a true 
deterioration, we chose to evaluate long-term cognitive outcomes which is more important to 
patients and their caregivers than changes that nay occur immediately in the short period after 
surgery and become reversible soon after hospital discharge. The incidence reported in our study 
supports the fact that POCD does exist in older adults three months after major elective 
noncardiac surgery with an incidence of about 16% when assessed using robust 
neuropsychological tests and defined using the Z-score method with the involvement of a 
nonsurgical control group to adjust for the learning effects. 
 
II. RISK FACTORS FOR POCD  
The multivariable analysis in our study showed that risk factors for POCD were carrying 
the ApoE4 allele, using one or more drugs with highly anticholinergic or sedative-hypnotic 
properties at home prior to surgery, and receiving sevoflurane for anesthesia. The current 
evidence in the literature about the association between these risk factors and POCD is still 
lacking and conflicting. 
In our study, the percentage of patients identified with POCD who had the ApoE4 allele 
was 35.7% compared to 11.3% who did not have the allele. Carrying the ApoE4 allele was 
associated with POCD three months after major noncardiac surgery in our study. This is not in 
agreement with the investigation by Abildstrom et al. who conducted a multicenter study in a 
total of 976 patients aged 40 years and older undergoing noncardiac surgery and could not find a 
difference in the incidence of POCD three months after surgery in patients with and without the 
ApoE4 allele (ApoE4 = 10.3%, non-ApoE4 = 8.4%; p = 0.40).9 However, the statistical power of 
this study was limited because of the lower incidence of POCD than expected and they also 
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included patients who are much younger than our patient group.9 The same finding was reported 
by McDonagh et al. who conducted a study in 394 patients older than 55 years old who 
underwent major noncardiac surgery.10 When they evaluated POCD one year after surgery in 291 
subjects, they could not find an association between ApoE4 genotype and POCD (ApoE4 = 
45.9%, non-APOE4 = 46.3%; p = 0.95).10 However, this study had an exaggerated incidence of 
POCD due to using a more liberal arbitrary definition of POCD. A recent study by Cai et al. 
showed an association of POCD with ApoE4 genotype three days after noncardiac surgery.11 
However, they used MMSE in identifying patients with POCD, which is no longer an accepted 
method to diagnose POCD or evaluate any changes in cognitive function in general. MMSE is 
only a screening instrument for dementia and, alone, cannot yield a diagnosis of dementia or 
cognitive problems.12 The mechanism by which ApoE4 may cause detrimental cognitive 
outcomes is still unclear.10 Potential etiologies include the specific effects on cerebral blood 
flow, altered responses to neuronal injury, cerebral metabolic decline, and increased cerebral 
microemboli secondary to increased atheroma burden.10 Also, there is support from several 
studies that ApoE4 may be linked to the inflammatory response to injury that may occur during 
surgery.10 ApoE4 can modulate this response by modifying glial activation, nitric oxide 
production, inflammatory cytokine production, and magnitude of cerebral edema.10 The 
association of ApoE4 gene with both POCD and AD can suggest that these two conditions may 
share similar mechanisms through β-amyloid and tau phosphorylation formation.13 
Our study is the first to investigate the association between using highly anticholinergic 
or sedative-hypnotic drugs at home prior to surgery and the risk of POCD three months after 
major noncardiac surgery. We only considered highly anticholinergic and sedative-hypnotic 
medications that have been included in the 2012 American Geriatrics Society updated Beers 
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criteria for potentially inappropriate medication use in older adults, as they are supported with 
strong evidence to cause harmful cognitive outcomes in older adults.14 Also, the anticholinergic 
drugs included in the list are only those with strong anticholinergic properties compiled from the 
Anticholinergic Risk Scale, Anticholinergic Drug Scale, and Anticholinergic Burden Scale 
which makes this list comprehensive.14 Highly anticholinergic drugs have been known for a long 
time to have negative cognitive outcomes especially in the older adult population.15-17 Carrière et 
al. studied a population-based cohort of 4128 women and 2784 men recruited from three French 
cities who had their cognitive function, clinical diagnosis of dementia, and anticholinergic 
evaluated at baseline, two, and four years later.18 The study found that older adults who were 
taking anticholinergic drugs were at increased risk for cognitive decline and dementia, and 
discontinuing anticholinergic drugs was associated with a decreased risk.18 Interestingly, there 
was an interaction between the use of anticholinergic drugs in women and carrying the ApoE4 
allele exposing patients with both to higher risk of cognitive dysfunction and dementia.18 Cai et 
al. conducted a retrospective cohort study with one-year follow-up of cognitive function in 3690 
older adults finding that the odds ratio for having a diagnosis of mild cognitive impairment 
(MCI) was 2.73 (1.27–5.87) among older adults who were exposed to three or more possible 
anticholinergic drugs for at least 90 days.19 Also, the long-term use of sedative-hypnotics, 
particularly benzodiazepines, is a risk factor for increased cognitive decline in older adults.20,21 
The cumulative burden of using these drugs at home prior to surgery can put the patients 
at higher risk to the insult from the surgery and anesthesia, which may expedite the progression 
of cognitive deterioration and make it more prominent few months after surgery. Our study 
showed that patients who were using at least one highly anticholinergic or sedative-hypnotic 
medications at home before surgery were at higher risk for POCD three months after surgery. 
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The reason we categorized the use of anticholinergic and sedative medications into only two 
groups (nonuse, and using one or more medications of this group) is that, with the exception of 
one patient who was using three medications and another who was using four medications of this 
group, all other patients were either nonusers or users of only one anticholinergic or sedative-
hypnotic medications. 
There is a growing interest in the involvement of individual anesthetic agents in the 
etiology of POCD. In our study, we compared the risk of POCD associated with the use of each 
individual anesthetic agent in study patients. The results showed that the use of sevoflurane for 
anesthesia was associated with higher risk of POCD three months after major noncardiac 
surgery. The relationship between sevoflurane and POCD or cognitive decline in general is still 
debatable. A study by Dong et al. showed that sevoflurane can induce apoptosis and increase β-
amyloid protein levels in mice which suggests that sevoflurane may promote AD 
neuropathogenesis.22 Le Freche et al. reached a similar conclusion when they demonstrated that 
sevoflurane exposure was associated with increased tau-phosphorylation and spatial memory 
deficits in mice one month after surgery.23 In this study, cognitive deterioration was transient at 
the first exposure to sevoflurane, but it became permanent with repeated exposure to the 
anesthetic agent.23 Liu et al. conducted a prospective, randomized parallel-group study in 180 
patients aged 65 to 75 years old with amnestic mild cognitive impairment, a subtype of mild 
cognitive impairment in which memory loss is the predominant symptom, who were randomly 
assigned to a sevoflurane, propofol or lidocaine epidural anesthesia group (n = 60 per group) 
during spinal surgery.24 They assessed patients’ cognitive function before and two years after 
surgery and obtained a cerebrospinal fluid sample by lumbar puncture from patients before the 
end of the surgery.24 They found that the number of cases who had progressive mild cognitive 
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impairment  was greater in the sevoflurane group, and not the propofol or lidocaine groups, than 
in the control group.24 Patients who developed progressive amnestic mild cognitive impairment 
had increased total tau and increased phosphorylated tau levels compared with those with stable 
mild cognitive impairment and the control group.24 On the other hand, sevoflurane has been 
suggested to have a protective effects on long-term cognitive function of Wistar rats by 
suppressing the inflammatory responses that occur during surgery.25 However, it is still unknown 
if these findings can be applied to humans, and whether the duration of anesthesia can play a role 
in changing the neuroprotective effect of sevoflurane during surgery to a detrimental effect on 
cognitive function with extended exposure. Kadoi et al. conducted a retrospective study on 109 
patients to test whether sevoflurane anesthesia had any ameliorative effects on POCD after 
CABG surgery.26 However, they could not find a significant association between POCD six 
months after surgery and the use of sevoflurane.26 These studies show that most of the research 
about the relationship between sevoflurane and the risk of cognitive deterioration conducted in 
humans reported either a protective effect or no difference in the risk between sevoflurane and 
other anesthetics agents. However, recent studies in animals showed significant and dose-
dependent deterioration of cognitive function with the use of sevoflurane. This warrants a need 
for further studies to compare the risk of POCD associated with the use of sevoflurane and other 
anesthetic agents in humans at variable doses and duration of exposure, and to confirm the 
possible tau phosphorylation mechanism by which sevoflurane might be causing cognitive 
deterioration after surgery. 
 
III. STUDY LIMITATIONS  
A major limitation of all studies investigating the incidence and risk factors of POCD is 
that there are major differences in research methodologies, including the neurocognitive batteries 
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used, the time interval between preoperative and postoperative assessment, and the definition and 
statistical methods used to identify patients with POCD. We used a robust study design that is 
consistent with the most recent guidelines and methodology of large studies particularly the 
ISPOCD studies allowing us to compare our findings with the findings of other well-designed 
studies. However, our study was limited by the small sample size due to the prospective nature of 
the study and the limited time and funding we had to recruit enough subjects. Despite the small 
sample size, we could still find a POCD incidence of 16% in our study subjects and this 
incidence is in agreement with current investigations of POCD after noncardiac surgery with 
robust methodology. 
One of the limitations of observational studies is that they can only identify associations, 
and not causality, between independent variables and the outcome of interest. Due to the 
observational nature of our study, it is possible that the association we found between POCD 
three months after major noncardiac surgery and carrying the ApoE4 allele, using at least one 
highly anticholinergic or sedative-hypnotic drug prior to surgery, and receiving sevoflurane for 
anesthesia was due to chance. An alternative explanation of the results or other underlying 
causes for POCD may exist. In order to confirm a cause-and-effect relationship between these 
risk factors and long-term POCD, randomized-controlled trials should be conducted. 
We had to conduct some of the follow-up cognitive testing sessions for patients in both 
surgical and nonsurgical groups at their residence if they were not willing to come back to the 
hospital. Theoretically, this could have affected the results of the study by performing the follow-
up cognitive testing at two different environments assuming that the hospital environment may 
be more stressful to study subjects compared to their own residence. However, we always 
recommended that patients do the follow-up testing at the hospital and we did not choose which 
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patients do the follow-up testing at their residence, and it was randomly based on the willingness 
of patients to come back to the hospital. However, we did not want to risk losing patients at 
follow-up in addition to the fact that cognitive testing done at the hospital was conducted in a 
very quiet private room with no distractions at all which may simulate patient’s home 
environment. 
Pain and anxiety can negatively affect performance of patients on neurocognitive testing 
and may cause them to be less motivated or focused on the test. Patients in the surgical group 
probably had pain and anxiety before the surgery during baseline cognitive testing. The level of 
pain and anxiety could have changed, probably decreased, by the time of follow-up testing three 
month after surgery which could have led to improvement of their performance on the tests. We 
did not assess the level of pain or anxiety at baseline or follow-up, and we do not know if this 
had an effect on the results of cognitive tests. We thought it would be too much burden and time-
consuming to assess pain and anxiety in addition to depression and sleep quality before each 
testing session. Conducting an extensive battery of tests can discourage many patients from 
participation in research. If not evaluating pain and anxiety before each testing session has 
caused any error, it would have underestimated the incidence of POCD in our study, because 
patients would be expected to have improved performance on cognitive tests. 
A large percentage of subjects in the patient and control groups refused to participate in 
the study. We do not have information about those who refused to participate since they did not 
sign the consent form. However, it is concerning whether the demographics and characteristics 
of subjects who did not participate in the study might be different from those who were included 
in the study. It is often the very old and more fragile patients who refuse to participate in studies 
like this particularly if they might be concerned about their cognitive function and they prefer not 
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to know about it. Some patients may also have very low educational level that they might be 
concerned about their ability to perform well on cognitive testing and the embarrassment they 
might experience especially with a computerized battery like the one in our study. We would 
expect to see a higher incidence of POCD if such patients were involved in the study. 
There was a higher representation of subjects with lower education level in the control 
group than the patient group, though the difference between the two groups in education level 
was not statistically significant. This difference could lead to different performance on cognitive 
testing resulting in a difference in the magnitude of learning effects that occur in controls as 
compared to patients, and consequently a potential bias in the incidence of POCD in the surgical 
group. 
Due to the small sample size, we had to combine anticholinergic and sedative-hypnotic 
drugs in one category. We also were not able to tests the relationship between the total drug 
burden taking into consideration the dose and regimen due to the small sample size. 
 
IV. FUTURE DIRECTIONS 
Future research should be directed towards conducting multicenter studies with larger 
samples, more diverse population, and expanded types of major noncardiac surgery to increase 
generalizability. Also, with appropriate funding and enough time, POCD should be assessed 
several times over a longer period of time to capture the changes that occur to the cognitive 
function of study subjects, and determine if POCD is a temporary or rather a permanent 
condition. Also, it would be interesting to determine if there is an association between POCD 
and AD since ApoE4 genotype has been associated with both conditions. The inflammatory 
theory has a great potential to explain the etiology of POCD. However, we were not able to 
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determine whether this is true in our study because we measured only one inflammatory 
biomarker and only once before surgery without postoperative evaluation. We were testing the 
hypothesis if patients with preoperative heightened inflammatory response may be at higher risk 
for POCD three months after noncardiac surgery. However, it would be actually more promising 
to test the hypothesis that patients who develop an inflammatory response during surgery may be 
at higher risk for POCD by measuring the blood levels of more than one inflammatory 
biomarkers that may play a role in the etiology of POCD (e.g., CRP, IL-1, IL-6, IL-8, TNF-
alpha) before and several times immediately after surgery at short intervals for at least 72 hours 
especially that we do not know yet when each of these markers peaks in blood levels after being 
released as an active response to inflammation during surgery. Our finding that using one or 
more highly anticholinergic or sedative-hypnotic medications at home prior to surgery was 
associated with POCD warrants future investigation of this relationship taking into consideration 
the dose and duration of use of each of these medications. It might be also interesting to 
investigate if discontinuing these drugs for a certain duration before surgery may decrease the 
risk of POCD after surgery. Also, future research can investigate the possible protective effect of 
certain anti-inflammatory drugs in decreasing the risk of POCD in patients undergoing different 
types of surgery and anesthesia. Our finding that sevoflurane was associated with POCD 
warrants further investigations by using randomized controlled trials comparing sevoflurane with 
other general anesthetics to make a definitive conclusion whether sevoflurane causes POCD, and 
if it does, whether it positions the patient at higher risk than other general anesthetics. It also 
important to further investigate the mechanism by which sevoflurane might be causing cognitive 
decline after surgery, and whether the tau phosphorylation theory is valid. 
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V. CONCLUSION 
POCD was present in about 16% of older adult patients three months after elective major 
noncardiac surgery. Carrying the ApoE4 allele, using one or more highly anticholinergic or 
sedative-hypnotic drugs prior to surgery, and receiving sevoflurane for anesthesia were risk 
factors for long-term POCD. Suggestions for future research in this area include using larger 
sample in a multicenter study, studying the association between the change in blood levels of 
several potential inflammatory biomarkers before and after surgery and its association with 
POCD, investigating the relationship between POCD and AD, studying the effect of dose and 
duration of use of anticholinergic and sedative-hypnotic medications before surgery on the risk 
of POCD, and investigating the protective effect of certain anti-inflammatory on decreasing the 
risk of POCD in older adults after different types of surgery and anesthesia. 
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APPENDIX A 
Approved Consent form for Study Surgical Group 
 
RESEARCH SUBJECT INFORMATION AND CONSENT FORM 
 
TITLE: Risk Factors for the Development of Postoperative Cognitive Dysfunction in Older 
Adults Undergoing Major Noncardiac Surgery 
 
VCU IRB PROTOCOL NUMBER: HM13608 
 
INVESTIGATORS: 
 
Patricia W. Slattum, PharmD, PhD 
Associate Professor and Director of Geriatric Pharmacotherapy Program 
Department of Pharmacotherapy and Outcomes Science 
VCU School of Pharmacy 
 
Clarence J. Biddle, CRNA, PhD 
Professor and Director of Research 
Department of Nurse Anesthesia 
VCU School of Allied Health Professions 
 
Osama A. Shoair, BPharm 
PhD Candidate, Geriatric Pharmacotherapy Program 
Department of Pharmacotherapy and Outcomes Science 
VCU School of Pharmacy 
 
This consent form may contain words that you do not understand. Please ask the study staff to 
explain any words or information that you do not clearly understand. You may take home an 
unsigned copy of this consent form to think about or discuss with family or friends before 
making your decision. 
 
 
PURPOSE OF THE STUDY 
 
The purpose of this study is to determine how often cognitive changes, such as changes in 
memory, attention, information processing speed, reaction time, and mental flexibility, occur 
after elective orthopedic surgery or neurosurgery in individuals 65 years or older and what the 
risk factors are for increasing the likelihood of developing such cognitive changes after these 
surgeries. Also, a secondary analysis will be done on the data collected to evaluate if there is a 
relationship between older patients’ medications and diseases and their cognitive function. 
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DESCRIPTION OF THE STUDY  
 
Before surgery, we will use computerized tests to evaluate your cognitive function, depression 
status, and quality of sleep. After surgery, we will test you to see if you have delirium (an acute 
condition that is characterized by feeling of confusion, difficulty in focusing, paying attention, or 
organizing thoughts) that can possibly happen in some individuals 24 – 36 hours after surgery. 
At discharge from the hospital, we will measure your cognitive function again using another set 
of computerized tests. Finally, we will evaluate your cognitive function, depression status, and 
sleep quality again 3 months after surgery and this will conclude the study. 
 
In addition to computerized testing, you may opt to provide a 5-mL blood sample before surgery 
for genetic testing that may help in the future to identify if there is a relationship between certain 
genes and development of cognitive changes in individuals 65 years and older after elective 
orthopedic surgery or neurosurgery. 
 
You may also opt to provide a 5-mL blood sample before surgery for testing of an inflammatory 
biomarker that may help in the future to identify if there is a relationship between preoperative 
high level of this biomarker and development of cognitive changes in individuals 65 years and 
older after elective orthopedic surgery or neurosurgery. 
 
Information about you and your surgical procedure, including but not limited to, age, sex, race, 
weight, height, educational level, alcohol intake, smoking status, previous surgeries, health 
conditions, current medications, type and duration of anesthesia, duration of surgery, and other 
surgical details will be collected from your medical records and evaluated in this study. 
 
Your participation in this study will last for up to 3 months after your surgery. Approximately 
150 subjects will participate in this study.  
 
Significant new findings developed during the course of this research which may relate to your 
willingness to continue participation will be provided to you. 
 
 
PROCEDURES 
 
If you decide to be in this research study, you will be asked to sign this consent form after you 
have had all your questions answered.  
 
During your visit to the preoperative assessment clinic, one of the study investigators will collect 
the following information about you: demographics, age/date of birth, sex, race/ethnicity, weight, 
height, educational level, computer familiarity, diagnosis on admission, previous/future 
surgeries, current medications, health conditions, smoking status, and alcohol consumption. He 
will also do a simple screening cognitive test to determine your eligibility for the study. This part 
will take about 30 minutes to complete. If you are eligible to participate in the study, one of the 
study investigators will evaluate your cognitive function, depression status, and sleep quality 
using a computer test that will take about 30 minutes to complete. 
 
 
 
96 
 
If you choose to provide a blood sample for testing of genetic and/or inflammatory biomarkers, 
two 5-mL blood samples will be withdrawn from you on the day of the surgery just before the 
induction of the anesthesia from the intravenous line that you will have by that time. Your 
privacy will be protected by storing your blood samples labeled with a barcode that does not 
contain your name or any personal information. Your personal information will be stored in a 
secure computer database at VCU. 
 
After your surgery and while you are still in the hospital, one test will be administered at 24 – 36 
hours after surgery to evaluate if you have delirium (an acute condition that is characterized by 
feeling of confusion, difficulty in focusing, paying attention, or organizing thoughts) after 
surgery. This test should take from 5 – 15 minutes to complete. Also, another set of cognitive 
tests will be administered at discharge from the hospital that should take about 30 minutes to 
complete. Information about your surgical procedure, including but not limited to, type and 
duration of anesthesia, duration of surgery, medications administered during surgery, and other 
surgical details will be obtained from your surgical record. 
 
Approximately 3 months after your surgery, another set of tests that measures your cognitive 
function, depression status, and sleep quality will be administered and should take about 30 
minutes. These measurements may take place at your doctor’s office during a regularly 
scheduled visit or at your residence. 
 
 
RISKS AND DISCOMFORTS 
 
The computerized tests of cognitive function, depression status, and sleep quality that you will 
take require only about 30 minutes per session to complete. The tests will be conducted in a 
private quiet room at Virginia Commonwealth University Health System (VCUHS) where you 
feel comfortable. 
 
If you opt to provide a blood sample for genetic analysis, only 5-mL (one teaspoonful) of blood 
will be withdrawn from you on the day of the surgery just before the induction of the anesthesia. 
Risks of blood drawing (venipuncture) include bleeding, bruising, and fainting. 
 
If you opt to provide a blood sample for biomarker analysis, only 5-mL (one teaspoonful) of 
blood will be withdrawn from you on the day of the surgery just before the induction of the 
anesthesia. Risks of blood drawing (venipuncture) include bleeding, bruising, and fainting. 
 
The tests you will take at each session may show that you are having depression and/or poor 
sleep quality. In either case, we will let you know immediately after the testing session and 
encourage you to seek help from your primary care physician. 
 
There is also a minimal risk of transmitting your personal identifying information to persons not 
on the study team. However, we minimize this risk by immediately de-identifying this 
information once we collect it from you and keeping it in a secure place that only study 
personnel have access to.  
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BENEFITS TO YOU AND OTHERS 
 
There is no direct benefit to you for participating in this study, but what is learned from this 
study may help other individuals undergoing elective orthopedic surgery or neurosurgery in the 
future identify, minimize, or prevent their risk for developing cognitive decline after these types 
of surgery and to understand the relationship between older patients’ medications and diseases 
and their cognitive function. 
 
If we find that your cognitive function appears to change during the study, you have experienced 
depression, or if you are concerned about your cognitive function or depression test results, the 
investigators will inform you and encourage you to see your primary care physician for further 
evaluation.  
 
 
COSTS 
 
There are no charges at all for the study visits, or any cognitive, depression, or sleep quality tests. 
There is also no cost at you to do blood genetic and/or biomarker testing if you opt to provide 
blood samples for the purpose of conducting these tests. 
 
 
PAYMENT FOR PARTICIPATION  
 
You will receive a $25 VISA® gift card for completing the first set of cognitive function, 
depression status, and sleep quality tests before your surgery. You will receive an additional $25 
VISA® gift card for completing the confusion test 24 – 36 hours after surgery and the second set 
of cognitive tests at discharge. You will receive a $50 VISA® gift card after the third set of 
cognitive function, depression status, and sleep quality tests at 3 months after surgery for a total 
of $100 in the form of VISA® gift cards if you completed all the study assessments. VISA® gift 
cards can be used wherever VISA® debit cards are accepted. The cards cannot be reloaded or 
used at ATM machines for cash withdrawals. 
 
 
ALTERNATIVE 
 
Your alternative is not to participate in this study. 
 
 
CONFIDENTIALITY  
 
Potentially identifiable information about you will consist of results from cognitive function, 
depression status, sleep quality tests, and data abstracted from your medical record. This data is 
being collected solely for research purposes. The data from cognitive function, depression status, 
and sleep quality tests will be securely stored separately from medical records in a locked 
research area and a secured computerized database at VCU.  
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If you opt to provide blood samples for genetic and/or biomarker testing, they will be securely 
stored at VCU School of Pharmacy. All personal identifying information will be kept in 
password-protected files. Access to all data will be limited to study personnel who have 
undergone special training on maintaining confidentiality of individuals participating in research. 
 
You should know that research data or medical information about you may be reviewed or 
copied by Virginia Commonwealth University. Although results of this research may be 
presented at meetings or in publications, identifiable personal information pertaining to 
participants will not be disclosed. 
 
 
DATA FROM COGNITIVE FUNCTION, DEPRESSION STATUS AND SLEEP 
QUALITY TESTING AND MEDICAL RECORD DATA 
 
I give permission for my data from cognitive function, depression status and sleep quality 
testing, and data from my medical record collected in this study to be stored and used for 
research related to cognitive impairment in older adults, including but not limited to, 
postoperative cognitive dysfunction and Alzheimer’s disease. 
 
 Yes 
 
 Yes, but I want to be contacted prior to any future use of my data for research 
 
 No 
 
 
GENETIC TESTING 
 
I opt to provide a 5-mL blood sample before surgery for genetic testing related to this research. I 
understand that study investigators will not disclose individual test results to me or any other 
third party. 
 
 Yes 
 
 No 
 
 
I give permission for my genetic testing results to be stored and used for future research related 
to cognitive impairment in older adults, including but not limited to, postoperative cognitive 
dysfunction and Alzheimer’s disease. 
 
 Yes 
 
 Yes, but I want to be contacted prior to any future use of my data for research 
 
 No 
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BIOMARKER TESTING 
 
I opt to provide a 5-mL blood sample before surgery for testing of inflammatory biomarkers 
related to this research. I understand that study investigators will not disclose individual test 
results to me or any other third party. 
 
 Yes 
 
 No 
 
I give permission for my biological markers testing results to be stored and used for future 
research related to cognitive impairment in older adults, including but not limited to, 
postoperative cognitive dysfunction and Alzheimer’s disease. 
 
 Yes 
 
 Yes, but I want to be contacted prior to any future use of my data for research 
 
 No 
 
 
VOLUNTARY PARTICIPATION AND WITHDRAWAL 
 
Your participation in this study is voluntary. You may decide not to participate in this study. 
Your decision not to take part will involve no penalty or loss of benefits to which you are 
otherwise entitled. 
 
If you do participate, you may freely withdraw from the study at any time. Your decision to 
withdraw will involve no penalty or loss of benefits to which you are otherwise entitled. You 
may also choose to participate in the study but not provide blood samples for genetic and/or 
biomarker testing. Your decision to participate in the study but not to provide blood samples will 
involve no penalty or loss of benefits to which you are otherwise entitled. 
 
Your participation in this study may be stopped at any time without your consent. The reasons 
might include, but not limited to, that you have not followed study instructions, there are 
administrative reasons that require your withdrawal, or that we have stopped the study. 
 
 
QUESTIONS 
 
In the future, you may have questions about your study participation. If you have any questions, 
complaints, or concerns about the research, contact: 
 
Patricia W. Slattum, PharmD, PhD 
Director, Geriatric Pharmacotherapy Program 
Virginia Commonwealth University 
 
 
100 
 
410 N 12th Street, Smith Building, Room 656A 
Richmond, VA 23298-0533 
PO Box 980533 
(804) 828-6355 
 
If you have questions about your rights as a research subject, you may contact: 
 
Office of Research 
Virginia Commonwealth University 
800 East Leigh Street, Suite 113 
PO Box 980568 
Richmond, VA  23298 
(804) 827-2157 
 
You may also contact this number for general questions, concerns or complaints about the 
research. Please, call this number if you cannot reach the research team or wish to talk to 
someone else. 
 
Do not sign this consent form unless you have had a chance to ask questions and have received 
satisfactory answers to all of your questions. Additional information about participation in 
research studies can be found at http://www.research.vcu.edu/irb/volunteers.htm. 
 
 
CONSENT  
 
I have been provided with an opportunity to read this consent form carefully. All of the questions 
that I wish to raise concerning this study have been answered. By signing this consent form, I 
have not waived any of the legal rights or benefits, to which I otherwise would be entitled.  My 
signature indicates that I freely consent to participate in this research study.  I will receive a copy 
of the consent form once I have agreed to participate. 
 
_______________________________________________________________________ 
Subject Name, printed  Subject Signature   Date 
 
 
________________________________________________ 
Name of Person Conducting Informed Consent  
Discussion / Witness  
(Printed) 
 
________________________________________________ ________________ 
Signature of Person Conducting Informed Consent   Date 
Discussion / Witness  
 
________________________________________________ ________________ 
Principal Investigator Signature (if different from above)   Date 
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APPENDIX B 
Approved Consent form for Study Nonsurgical Group 
 
RESEARCH SUBJECT INFORMATION AND CONSENT FORM 
 
TITLE: Risk Factors for the Development of Postoperative Cognitive Dysfunction in Older 
Adults Undergoing Major Noncardiac Surgery 
 
VCU IRB PROTOCOL NUMBER: HM13608 
 
INVESTIGATORS: 
 
Patricia W. Slattum, PharmD, PhD 
Associate Professor and Director of Geriatric Pharmacotherapy Program 
Department of Pharmacotherapy and Outcomes Science 
VCU School of Pharmacy 
 
Clarence J. Biddle, CRNA, PhD 
Professor and Director of Research 
Department of Nurse Anesthesia 
VCU School of Allied Health Professions 
 
Osama A. Shoair, BPharm 
PhD Candidate, Geriatric Pharmacotherapy Program 
Department of Pharmacotherapy and Outcomes Science 
VCU School of Pharmacy 
 
This consent form may contain words that you do not understand. Please ask the study staff to 
explain any words or information that you do not clearly understand. You may take home an 
unsigned copy of this consent form to think about or discuss with family or friends before 
making your decision. 
 
 
PURPOSE OF THE STUDY 
 
The purpose of this study is to determine how often cognitive changes, such as changes in 
memory, attention, information processing speed, reaction time, and mental flexibility, occur 
after elective orthopedic surgery or neurosurgery in patients 65 years and older and to identify 
the risk factors for increasing the likelihood of such cognitive changes after these surgeries. Also, 
a secondary analysis will be done on the data collected to evaluate if there is a relationship 
between older patients’ medications and diseases and their cognitive function. 
 
In order to accurately measure changes in cognitive function in older patients undergoing surgery 
in our study, we need to recruit a control group of older adults who are not undergoing surgery 
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within 3 months and measure their cognitive function at the same time interval as the patients in 
our study (baseline and 3 months later) to compare the change in cognitive function between the 
patient and control groups.  
 
 
DESCRIPTION OF THE STUDY  
 
We will use a computer program called CNS Vital Signs™ to assess your cognitive function, 
depression status, and sleep quality at your first meeting with us and again 3 months later to see 
if there is any significant change in your cognitive function. It will take about 30 minutes to 
complete all the tests at each of the two sessions. These tests may take place at your residence or 
at a private quiet room at VCU Health System. 
 
 
Your participation in this study will last for about 3 months after your first interview with the 
study team. Approximately 100 subjects will participate in this study as controls. Significant new 
findings developed during the course of this research which may relate to your willingness to 
continue participation will be provided to you. 
 
 
PROCEDURES 
 
If you decide to be in this research study as a control, you will be asked to sign this consent form 
after you have had all your questions answered.  
 
If you decide to be part of the study, the research team will conduct their first interview with you 
either at VCU Health System or at your residence. During this first interview, the study 
investigators will collect information about your age, gender, race, education level, computer 
familiarity, smoking status, alcohol consumption, health conditions, future surgeries, and current 
medications. 
 
We will also do a simple screening cognitive test to determine your eligibility for the study. If 
you are eligible to participate in the study, one of the study investigators will evaluate your 
cognitive function, depression status, and sleep quality using a computer test that will take about 
30 minutes to complete. 
 
Approximately 3 months after your first interview, we will arrange another meeting with you at 
VCU Health System or at your residence to evaluate your cognitive function, depression status, 
and sleep quality again using the same tests from the first interview which will take about 30 
minutes to complete. We will also check if there has been any change to your current 
medications. 
 
RISKS AND DISCOMFORTS 
 
The computerized tests of cognitive function, depression status, and sleep quality that you will 
take require only about 30 minutes per session to complete. The tests will be conducted in a 
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private quiet room at VCU Health System or your residence where you feel comfortable. There 
are times in between different tests when you can take a break if you want to. If you feel 
exhausted at any time, you can stop the testing session. 
 
The tests you will take at each session may show that you are having depression and/or poor 
sleep quality. In either case, we will let you know immediately after the testing session and 
encourage you to seek help from your primary care physician. 
 
There is also a minimal risk of transmitting your personal identifying information to persons not 
on the study team. However, we minimize this risk by immediately de-identifying this 
information once we collect it from you and keeping it in a secure place that only study 
personnel have access to. 
 
BENEFITS TO YOU AND OTHERS 
 
There is no direct benefit to you for participating in this study, but what is learned from this 
study by comparing the change in cognitive function between study patients and controls from 
baseline to the 3-month follow-up may help in the future to minimize or prevent the risk for 
developing cognitive decline after elective orthopedic surgery or neurosurgery in older adults 
and to understand the relationship between older patients’ medications and diseases and their 
cognitive function. 
 
If the cognitive screening test shows that you have a cognitive problem or if we find that you 
may have depression or poor sleep quality, the study investigators will inform you and encourage 
you to talk to your primary care physician for further evaluation. 
 
COSTS 
 
There are no charges at all for the study visits, or any cognitive, depression, or sleep quality tests. 
 
 
PAYMENT FOR PARTICIPATION  
 
You will receive a $25 VISA® gift card for completing the cognitive function, depression status, 
and sleep quality tests at your first interview. You will receive an additional $50 VISA® gift 
cards for completing the cognitive function, depression status, and sleep quality tests at your 
second interview for a total of $75 in the form of VISA® gift cards if you complete both study 
assessments. VISA® gift cards can be used wherever VISA® debit cards are accepted. The cards 
cannot be reloaded or used at ATM machines for cash withdrawals. 
 
 
ALTERNATIVE 
 
Your alternative is not to participate in this study. 
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CONFIDENTIALITY  
 
Information about your age, gender, race, education level, computer familiarity, smoking status, 
alcohol consumption, health conditions, future surgeries, and current medications in addition to 
your results of cognitive function, depression status, and sleep quality tests is being collected 
solely for research purposes. This data will be securely stored in a locked research area and a 
secured computerized database at VCU. Access to all data will be limited to study personnel who 
have undergone special training on maintaining confidentiality of individuals participating in 
research. 
 
You should know that research data or medical information about you may be reviewed or 
copied by Virginia Commonwealth University. Although results of this research may be 
presented at meetings or in publications, identifiable personal information pertaining to 
participants will not be disclosed. 
 
 
FUTURE USE OF DATA 
 
I give permission for my data collected in this study to be stored and used for research related to 
cognitive impairment in older adults. (Please, check and initial your choice) 
 
 Yes ______ 
 
 Yes, but I want to be contacted prior to any future use of my data for research ______ 
 
 No ______ 
 
 
VOLUNTARY PARTICIPATION AND WITHDRAWAL 
 
Your participation in this study is voluntary. You may decide not to participate in this study. 
Your decision not to take part will involve no penalty or loss of benefits to which you are 
otherwise entitled. If you participate, you may freely withdraw from the study at any time. Your 
decision to withdraw will involve no penalty or loss of benefits you are otherwise entitled to.  
 
Your participation in this study may be stopped at any time without your consent. The reasons 
might include, limited to, that you have not followed study instructions, there are administrative 
reasons that require your withdrawal, or that we have stopped the study. 
 
 
QUESTIONS 
 
In the future, you may have questions about your study participation. If you have any questions, 
complaints, or concerns about the research, contact the study principal investigator: 
 
Patricia W. Slattum, PharmD, PhD 
Director, Geriatric Pharmacotherapy Program 
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Virginia Commonwealth University 
410 N. 12th Street, Smith Building, Room 656A, P.O. Box 980533 
Richmond, VA 23298-0533 
(804) 828-6355 
If you have questions about your rights as a research subject, you may contact: 
 
Office of Research 
Virginia Commonwealth University 
800 East Leigh Street, Suite 113 
PO Box 980568 
Richmond, VA  23298 
(804) 827-2157 
 
You may also contact this number for general questions, concerns or complaints about the 
research. Please, call this number if you cannot reach the research team or wish to talk to 
someone else. 
 
Do not sign this consent form unless you have had a chance to ask questions and have received 
satisfactory answers to all of your questions. Additional information about participation in 
research studies can be found at http://www.research.vcu.edu/irb/volunteers.htm 
 
 
CONSENT  
 
I have been provided with an opportunity to read this consent form carefully. All of the questions 
that I wish to raise concerning this study have been answered. By signing this consent form, I 
have not waived any of the legal rights or benefits, to which I otherwise would be entitled.  My 
signature indicates that I freely consent to participate in this research study.  I can request a copy 
of the signed consent form once I have agreed to participate. 
 
_______________________________________________________________________ 
Subject Name, printed  Subject Signature   Date 
 
________________________________________________ 
Name of Person Conducting Informed Consent  
Discussion / Witness  
(Printed) 
 
________________________________________________ ________________ 
Signature of Person Conducting Informed Consent   Date 
Discussion / Witness  
 
 
______________________________________________  ________________ 
Principal Investigator Signature (if different from above)   Date 
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the School of Pharmacy at Misr International University. Osama received a Certificate in Aging 
Studies from Virginia Commonwealth University, Richmond, Virginia in 2013. He also 
completed the Preparing Future Faculty program at Virginia Commonwealth University and 
received the Certificate of Teaching Excellence at the conclusion of the program. Osama 
published a review article as a first author on medication-related dizziness in older adults in 
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